CUMULATIVE SUPPLEMENT 03
March 2008



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

28th EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2008

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

28th EDITION

Cumulative Supplement 03

March 2008

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

28th EDITION

CUMULATIVE SUPPLEMENT 03
March 2008

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 28th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 27th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 28th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@cder.fda.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7500 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BRISTOL MYERS SQUIBB MEDICAL IMAGING (BRISTOL MYERS)	LANTHEUS MEDICAL IMAGING INC (LANTHEUS MEDCL)
CIS US INC (CIS)	PHARMALUCENCE INC (PHARMALUCENCE)
RELIANT PHARMACEUTICALS LLC (RELIANT PHARMS)	SMITHKLINE BBECHAM CORP DBA GLAXOSMITHKLINE (SMITHKLINE BEECHAM)

1.4 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.fda.gov/cder/ob/default.htm, has been available on the internet and has become the updated-every-month Orange Book. The

Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Annual Edition. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov/; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/cder/orange/obreadme.htm . The drug product text files are provided in eobzip.exe and eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for

marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2007	MAR 2008	JUN 2007	SEPT 2007
DRUG PRODUCTS LISTED	12302	12459	11900	12130
SINGLE SOURCE	2489	2514	2483	2494
	(20.2%)	(20.2%)	(20.9%)	(20.6%)
MULTISOURCE	9724	9856	9328	9547
	(79.0%)	(79.1%)	(78.4%)	(78.7%)
THERAPEUTICALLY EQUIVALENT	9571	9703	9148	9394
	(77.8%)	(77.9%)	(76.9%)	(77.4%)
NOT THERAPEUTICALLY EQUIVALENT	153	153	180	153
	(1.2%)	(1.2%)	(1.5%)	(1.3%)
EXCEPTIONS[1]	89	89	89	89
	(0.7%)	(0.7%)	(0.7%)	(0.7%)
NEW MOLECULAR ENTITIES APPROVED	7	7	7	10
NUMBER OF APPLICANTS	693	710	679	683

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.6 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA New drug product approval usually in the supplement month.

CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HYDROCHLORIDE

AB		AMNEAL PHARM	EQ 200MG BASE	N75047	001	Dec 30, 1999	Feb	CAHN
AB			EQ 400MG BASE	N75047	002	Dec 30, 1999	Feb	CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	MUTUAL PHARM	300MG;15MG	N89671	001	Feb 10, 1988	Feb	DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	MIKART	500MG/15ML;5MG/15ML	N89557	001	Apr 29, 1992	Feb	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
PERCOCET

AA	+	ENDO PHARMS	325MG;5MG	N40330	002	Jun 25, 1999	Feb	CRLD
	@		325MG;5MG	N85106	002		Feb	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

AB		CONCORD LABS NJ	650MG;100MG	N77821	001	Feb 11, 2008	Jan	NEWA

ACETOHEXAMIDE

TABLET; ORAL
ACETOHEXAMIDE

	@	BARR	250MG	N70869	001	Feb 09, 1987	Feb	DISC
	@		500MG	N70870	001	Feb 09, 1987	Jan	DISC
		WATSON LABS	250MG	N71893	001	Nov 25, 1987	Feb	CTEC
	+		500MG	N71894	001	Nov 25, 1987	Jan	CRLD

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

	@	APOTHECON	200MG	N74889	001	Oct 31, 1997	Feb	DISC

TABLET; ORAL
ACYCLOVIR

	@	APOTHECON	400MG	N74891	001	Oct 31, 1997	Feb	DISC
	@		800MG	N74891	002	Oct 31, 1997	Feb	DISC

ALBUTEROL SULFATE

SYRUP; ORAL
ALBUTEROL SULFATE

	@	ACTAVIS MID ATLANTIC	EQ 2MG BASE/5ML	N75262	001	Mar 30, 1999	Feb	DISC

TABLET; ORAL
ALBUTEROL SULFATE

	@	WATSON LABS	EQ 4MG BASE	N72630	001	Jan 31, 1991	Feb	DISC

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

AB		BARR	EQ 70MG BASE	N76184	001	Feb 06, 2008	Jan	NEWA
AB		TEVA PHARMS	EQ 5MG BASE	N75710	001	Feb 06, 2008	Jan	NEWA
AB			EQ 10MG BASE	N75710	002	Feb 06, 2008	Jan	NEWA
AB			EQ 35MG BASE	N75710	003	Feb 06, 2008	Jan	NEWA
AB			EQ 40MG BASE	N75710	004	Feb 06, 2008	Jan	NEWA
AB			EQ 70MG BASE	N75710	005	Feb 06, 2008	Jan	NEWA

FOSAMAX

AB		MERCK AND CO INC	EQ 5MG BASE	N20560	003	Apr 25, 1997	Jan	CFTG
AB			EQ 10MG BASE	N20560	001	Sep 29, 1995	Jan	CFTG
AB			EQ 35MG BASE	N20560	004	Oct 20, 2000	Jan	CFTG
AB			EQ 40MG BASE	N20560	002	Sep 29, 1995	Jan	CFTG
AB	+		EQ 70MG BASE	N20560	005	Oct 20, 2000	Jan	CFTG

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

TEKTURNA HCT

		NOVARTIS	EQ 150MG BASE;12.5MG	N22107	001	Jan 18, 2008	Jan	NEWA
			EQ 150MG BASE;25MG	N22107	002	Jan 18, 2008	Jan	NEWA
			EQ 300MG BASE;12.5MG	N22107	003	Jan 18, 2008	Jan	NEWA
	+		EQ 300MG BASE;25MG	N22107	004	Jan 18, 2008	Jan	NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

>D>		GLAXOSMITHKLINE	EQ 0.5MG BASE	N21107	002	Dec 23, 2003	Mar	CAHN
>D>	+		EQ 1MG BASE	N21107	001	Feb 09, 2000	Mar	CAHN
>A>		PROMETHEUS LABS	EQ 0.5MG BASE	N21107	002	Dec 23, 2003	Mar	CAHN
>A>	+		EQ 1MG BASE	N21107	001	Feb 09, 2000	Mar	CAHN

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

		@ TEVA	0.25MG	N74085	001	Feb 16, 1994	Feb	DISC
		@	0.5MG	N74085	002	Feb 16, 1994	Feb	DISC
		@	1MG	N74085	003	Feb 16, 1994	Feb	DISC
		@	2MG	N74085	004	Feb 26, 1996	Feb	DISC

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

		@ TEVA PHARMS	50MG/5ML	N73115	001	Aug 23, 1991	Feb	DISC

AMIFOSTINE

INJECTABLE; INJECTION

>A>		AMIFOSTINE						
>A>	AP	SUN PHARM INDS	500MG/VIAL	N77126	001	Mar 14, 2008	Mar	NEWA

ETHYOL

>D>	+	MEDIMMUNE ONCOLOGY	500MG/VIAL	N20221	001	Dec 08, 1995	Mar	CFTG
>A>	AP +		500MG/VIAL	N20221	001	Dec 08, 1995	Mar	CFTG

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION
AMIODARONE HYDROCHLORIDE

AP	HIKMA FARMACEUTICA	50MG/ML	N77234	001	Feb 25, 2008	Feb	NEWA

TABLET; ORAL
AMIODARONE HYDROCHLORIDE

	@ TEVA	200MG	N74895	001	Apr 16, 1999	Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

	@ GENPHARM	EQ 2.5MG BASE	N77362	001	Jul 09, 2007	Feb	DISC
	@	EQ 5MG BASE	N77362	002	Jul 09, 2007	Feb	DISC
	@	EQ 10MG BASE	N77362	003	Jul 09, 2007	Feb	DISC
AB	INTERPHARM	EQ 2.5MG BASE	N78477	001	Jan 16, 2008	Jan	NEWA
AB		EQ 5MG BASE	N78477	002	Jan 16, 2008	Jan	NEWA
AB		EQ 10MG BASE	N78477	003	Jan 16, 2008	Jan	NEWA
AB	MATRIX LABS LTD	EQ 2.5MG BASE	N78224	001	Feb 27, 2008	Feb	NEWA
AB		EQ 5MG BASE	N78224	002	Feb 27, 2008	Feb	NEWA
AB		EQ 10MG BASE	N78224	003	Feb 27, 2008	Feb	NEWA
AB	MUTUAL PHARMA	EQ 2.5MG BASE	N78081	001	Jan 31, 2008	Jan	NEWA
AB		EQ 5MG BASE	N78081	002	Jan 31, 2008	Jan	NEWA
AB		EQ 10MG BASE	N78081	003	Jan 31, 2008	Jan	NEWA

AMOXICILLIN

TABLET, EXTENDED RELEASE; ORAL
MOXATAG

+	MIDDLEBROOK PHARMS	775MG	N50813	001	Jan 23, 2008	Jan	NEWA

ATENOLOL

INJECTABLE; INJECTION
TENORMIN

	@ ASTRAZENECA	0.5MG/ML	N19058	001	Sep 13, 1989	Feb	DISC

TABLET; ORAL
ATENOLOL

	@ PLIVA	25MG	N74101	001	Jul 17, 1997	Feb	DISC
	@	50MG	N74101	002	Jul 17, 1997	Feb	DISC
	@	100MG	N74101	003	Jul 17, 1997	Feb	DISC
	@ SANDOZ	25MG	N74265	001	Feb 28, 1994	Feb	DISC
	@	50MG	N74265	002	Feb 28, 1994	Feb	DISC
	@	100MG	N74265	003	Feb 28, 1994	Feb	DISC
	@ SCS	50MG	N73676	001	Oct 30, 1992	Feb	DISC
	@	100MG	N73676	002	Oct 30, 1992	Feb	DISC

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON-PLUS

	@ BAXTER HLTHCARE CORP	0.14MG/ML;10MG/ML	N19677	001	Nov 06, 1991	Feb	DISC
	@	0.14MG/ML;10MG/ML	N19678	001	Nov 06, 1991	Feb	DISC

AZITHROMYCIN

TABLET; ORAL
AZITHROMYCIN

AB	WOCKHARDT	EQ 250MG BASE	N65404	001	Feb 11, 2008	Jan	NEWA
AB		EQ 500MG BASE	N65405	001	Feb 11, 2008	Jan	NEWA

TABLET; ORAL
AZITHROMYCIN

AB	WOCKHARDT	EQ 600MG BASE	N65302	003	Feb 11, 2008	Jan	NEWA

AZTREONAM

INJECTABLE; INJECTION
AZACTAM

@	BRISTOL MYERS SQUIBB	500MG/VIAL	N50580	001	Dec 31, 1986	Jan	DISC

>A> BENDAMUSTINE HYDROCHLORIDE

>A> POWDER; IV (INFUSION)
>A> TREANDA

>A> +	CEPHALON	100MG/VIAL	N22249	001	Mar 20, 2008	Mar	NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL
NADOLOL AND BENDROFLUMETHAZIDE

AB	MYLAN	5MG;40MG	N78688	001	Feb 15, 2008	Feb	NEWA
AB		5MG;80MG	N78688	002	Feb 15, 2008	Feb	NEWA

BENZONATATE

CAPSULE; ORAL
BENZONATATE

AA	ORIT LABS LLC	100MG	N40682	001	Jul 30, 2007	Jan	CAHN
AA		200MG	N40682	002	Jul 30, 2007	Jan	CAHN
>A> AA	SUN PHARM INDS INC	100MG	N40587	001	Mar 19, 2008	Mar	NEWA
>A> AA		200MG	N40587	002	Mar 19, 2008	Mar	NEWA

BENZTROPINE MESYLATE

TABLET; ORAL
BENZTROPINE MESYLATE

AA	ACTAVIS TOTOWA	0.5MG	N40699	001	Feb 14, 2008	Jan	NEWA
AA		1MG	N40705	001	Feb 14, 2008	Jan	NEWA
AA		2MG	N40706	001	Feb 14, 2008	Jan	NEWA
@	MUTUAL PHARM	1MG	N81264	001	Jan 23, 1992	Feb	DISC
@		2MG	N81265	001	Jan 23, 1992	Feb	DISC

BETHANECHOL CHLORIDE

TABLET; ORAL
BETHANECHOL CHLORIDE

>A> AA	LANNETT	5MG	N40703	001	Mar 27, 2008	Mar	NEWA
>A> AA		10MG	N40704	001	Mar 27, 2008	Mar	NEWA
>A> AA		25MG	N40678	003	Mar 27, 2008	Mar	NEWA
>A> AA		50MG	N40677	001	Mar 27, 2008	Mar	NEWA

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLEOMYCIN SULFATE

AP	ABRAXIS PHARM	EQ 15 UNITS BASE/VIAL	N65185	001	Jan 28, 2008	Jan	NEWA
AP		EQ 30 UNITS BASE/VIAL	N65185	002	Jan 28, 2008	Jan	NEWA
AP	BEDFORD	EQ 15 UNITS BASE/VIAL	N65042	002	Oct 17, 2001	Jan	CTNA
AP		EQ 30 UNITS BASE/VIAL	N65042	001	Oct 17, 2001	Jan	CTNA
AP	HOSPIRA	EQ 15 UNITS BASE/VIAL	N65031	001	Mar 10, 2000	Jan	CTNA
AP		EQ 30 UNITS BASE/VIAL	N65031	002	Mar 10, 2000	Jan	CTNA
AP	PHARMACHEMIE BV	EQ 15 UNITS BASE/VIAL	N65201	001	Dec 13, 2007	Jan	CTNA
AP	TEVA PARENTERAL	EQ 15 UNITS BASE/VIAL	N65033	001	Jun 27, 2000	Jan	CTNA

		INJECTABLE; INJECTION						
		BLEOMYCIN SULFATE						
	AP	TEVA PARENTERAL	EQ 30 UNITS BASE/VIAL	N65033	002	Jun 27, 2000	Jan	CTNA
		BRIMONIDINE TARTRATE						
		SOLUTION/DROPS; OPHTHALMIC						
		BRIMONIDINE TARTRATE						
	AT	SANDOZ	0.2%	N78075	001	Jan 30, 2008	Jan	NEWA
		BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE						
		SYRUP; ORAL						
		BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE						
		@ MORTON GROVE	12.5MG/5ML;10MG/5ML	N88626	001	Oct 12, 1984	Feb	DISC
		BUPROPION HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE; ORAL						
		BUPROPION HYDROCHLORIDE						
>A>	AB1	ACTAVIS	150MG	N77455	002	Mar 12, 2008	Mar	NEWA
>D>	AB1		150MG	N77475	001	Mar 12, 2008	Mar	CTEC
>A>	AB2		150MG	N77475	001	Mar 12, 2008	Mar	CTEC
	AB1		150MG	N77475	001	Mar 12, 2008	Feb	NEWA
		CAFFEINE CITRATE						
		SOLUTION; ORAL						
		CAFFEINE CITRATE						
	AA	ABRAXIS PHARM PRODS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N78002	001	Jan 31, 2008	Jan	NEWA
		CALCITRIOL						
		INJECTABLE; INJECTION						
		CALCITRIOL						
	AP	AKORN	0.001MG/ML	N78066	001	Jan 29, 2008	Jan	NEWA
	AP		0.002MG/ML	N78066	002	Jan 29, 2008	Jan	NEWA
		CALCIUM ACETATE						
		CAPSULE; ORAL						
		CALCIUM ACETATE						
	AB	ROXANE	EQ 169MG CALCIUM	N77728	001	Feb 26, 2008	Feb	NEWA
		PHOSLO GELCAPS						
	AB +	FRESENIUS MEDCL	EQ 169MG CALCIUM	N21160	003	Apr 02, 2001	Feb	CFTG
		TABLET; ORAL						
		CALCIUM ACETATE						
	+	ROXANE	EQ 169MG CALCIUM	N77693	001	Jan 30, 2008	Jan	NEWA
		CAPTOPRIL						
		TABLET; ORAL						
		CAPTOPRIL						
		@ SANDOZ	12.5MG	N74481	001	Feb 13, 1996	Feb	DISC
		@	12.5MG	N74519	001	Feb 13, 1996	Feb	DISC
		@	25MG	N74481	002	Feb 13, 1996	Feb	DISC
		@	25MG	N74519	002	Feb 13, 1996	Feb	DISC
		@	50MG	N74481	003	Feb 13, 1996	Feb	DISC
		@	50MG	N74519	003	Feb 13, 1996	Feb	DISC
		@	100MG	N74481	004	Feb 13, 1996	Feb	DISC
		@	100MG	N74519	004	Feb 13, 1996	Feb	DISC
		@ WATSON LABS	12.5MG	N74576	001	Apr 23, 1996	Feb	DISC

TABLET; ORAL
CAPTOPRIL

		@ WATSON LABS	25MG	N74576	002	Apr 23, 1996	Feb	DISC
		@	50MG	N74576	003	Apr 23, 1996	Feb	DISC
		@	100MG	N74576	004	Apr 23, 1996	Feb	DISC

CARBINOXAMINE MALEATE

SOLUTION; ORAL
CARBINOXAMINE MALEATE

AA		BOCA PHARMA	4MG/5ML	N40814	001	Feb 26, 2008	Feb	NEWA
AA	+	MIKART	4MG/5ML	N40458	001	Apr 25, 2003	Feb	CTEC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL
CEFADROXIL

AB		HIKMA	EQ 500MG BASE	N65311	001	Feb 07, 2006	Jan	CAHN

FOR SUSPENSION; ORAL
CEFADROXIL

AB		LUPIN	EQ 250MG BASE/5ML	N65396	001	Feb 21, 2008	Feb	NEWA
AB			EQ 500MG BASE/5ML	N65396	002	Feb 21, 2008	Feb	NEWA

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
KEFZOL

>D>		@ ACS DOBFAR	EQ 500MG BASE/VIAL	N61773	002		Mar	CMFD
>A>	AP		EQ 500MG BASE/VIAL	N61773	002		Mar	CMFD
>D>		@	EQ 1GM BASE/VIAL	N61773	003		Mar	CMFD
>A>	AP		EQ 1GM BASE/VIAL	N61773	003		Mar	CMFD
>D>		@	EQ 10GM BASE/VIAL	N61773	004		Mar	CMFD
>A>	AP		EQ 10GM BASE/VIAL	N61773	004		Mar	CMFD

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

>A>	AP	ACS DOBFAR	1GM/VIAL	N65441	001	Mar 20, 2008	Mar	NEWA
>A>	AP		2GM/VIAL	N65441	002	Mar 20, 2008	Mar	NEWA

CEFPROZIL

TABLET; ORAL
CEFPROZIL

>A>	AB	APOTEX INC	250MG	N65327	001	Mar 26, 2008	Mar	NEWA
>A>	AB		500MG	N65327	002	Mar 26, 2008	Mar	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP		LUITPOLD	EQ 250MG BASE/VIAL	N65305	001	Jan 11, 2008	Jan	NEWA
AP			EQ 500MG BASE/VIAL	N65305	002	Jan 11, 2008	Jan	NEWA
AP			EQ 1GM BASE/VIAL	N65305	003	Jan 11, 2008	Jan	NEWA
AP			EQ 2GM BASE/VIAL	N65305	004	Jan 11, 2008	Jan	NEWA

CEFUROXIME AXETIL

FOR SUSPENSION; ORAL
CEFTIN

AB		GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N50672	001	Jun 30, 1994	Jan	CFTG
AB	+		EQ 250MG BASE/5ML	N50672	002	Apr 29, 1997	Jan	CFTG

		FOR SUSPENSION; ORAL							
		CEFUROXIME AXETIL							
	AB	RANBAXY	EQ 125MG BASE/5ML	N65323	001	Feb 05, 2008	Jan	NEWA	
	AB		EQ 250MG BASE/5ML	N65323	002	Feb 05, 2008	Jan	NEWA	
		TABLET; ORAL							
		CEFUROXIME AXETIL							
	AB	ORCHID HLTHCARE	EQ 125MG BASE	N65359	001	Feb 15, 2008	Jan	NEWA	
	AB		EQ 250MG BASE	N65359	002	Feb 15, 2008	Jan	NEWA	
	AB		EQ 500MG BASE	N65359	003	Feb 15, 2008	Jan	NEWA	
		CETIRIZINE HYDROCHLORIDE							
		SYRUP; ORAL							
		ZYRTEC							
	+	MCNEIL CONSUMER	5MG/5ML	N20346	001	Sep 27, 1996	Jan	CAHN	
		CICLESONIDE							
		AEROSOL, METERED; INHALATION							
		ALVESCO							
		NYCOMED US	0.08MG/INH	N21658	002	Jan 10, 2008	Jan	NEWA	
	+		0.16MG/INH	N21658	003	Jan 10, 2008	Jan	NEWA	
		CIPROFLOXACIN							
		INJECTABLE; INJECTION							
		CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	+	BAYER PHARMS	200MG/100ML	N19857	001	Dec 26, 1990	Mar	CFTG	
>A>	AP +		200MG/100ML	N19857	001	Dec 26, 1990	Mar	CFTG	
>A>	AP +		400MG/200ML	N19857	002	Dec 26, 1990	Mar	CFTG	
>A>		CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER							
>A>	AP	ACS DOBFAR INFO SA	200MG/100ML	N78252	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N78252	002	Mar 18, 2008	Mar	NEWA	
>A>	AP	BAXTER HLTHCARE	200MG/100ML	N77888	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N77888	002	Mar 18, 2008	Mar	NEWA	
>A>	AP	BEDFORD	200MG/100ML	N78114	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N78114	002	Mar 18, 2008	Mar	NEWA	
>A>	AP	CLARIS LIFESCIENCES	200MG/100ML	N78024	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N78024	002	Mar 18, 2008	Mar	NEWA	
>A>	AP	HOSPIRA	200MG/100ML	N77753	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N77753	002	Mar 18, 2008	Mar	NEWA	
>A>	AP	TEVA PARENTERAL	200MG/100ML	N77138	001	Mar 18, 2008	Mar	NEWA	
>A>	AP		400MG/200ML	N77138	002	Mar 18, 2008	Mar	NEWA	
		CIPROFLOXACIN HYDROCHLORIDE							
		SOLUTION/DROPS; OPHTHALMIC							
		CIPROFLOXACIN HYDROCHLORIDE							
	AT	PHARMAFORCE	EQ 0.3% BASE	N78598	001	Jan 16, 2008	Jan	NEWA	
		CITALOPRAM HYDROBROMIDE							
		TABLET; ORAL							
		CITALOPRAM HYDROBROMIDE							
>D>	AB	KALI LABS	EQ 10MG BASE	N77042	001	Nov 05, 2004	Mar	CAHN	
>D>	AB		EQ 20MG BASE	N77042	002	Nov 05, 2004	Mar	CAHN	
>D>	AB		EQ 40MG BASE	N77042	003	Nov 05, 2004	Mar	CAHN	
>A>	AB	MATRIX LABS INC	EQ 10MG BASE	N77042	001	Nov 05, 2004	Mar	CAHN	
>A>	AB		EQ 20MG BASE	N77042	002	Nov 05, 2004	Mar	CAHN	
>A>	AB		EQ 40MG BASE	N77042	003	Nov 05, 2004	Mar	CAHN	
>A>	AB	NATCO PHARMA LTD	EQ 20MG BASE	N77141	002	Apr 10, 2008	Mar	NEWA	

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

>A>	AB	NATCO PHARMA LTD	EQ 40MG BASE	N77141	001	Apr 10, 2008	Mar	NEWA

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL
CLOBETASOL PROPIONATE

	AB	PERRIGO ISRAEL	0.05%	N77763	001	Mar 10, 2008	Feb	NEWA

OLUX

	AB +	CONNETICS	0.05%	N21142	001	May 26, 2000	Feb	CFTG

CLOPIDOGREL BISULFATE

TABLET; ORAL
CLOPIDOGREL BISULFATE

	AB	DR REDDYS LABS INC	EQ 75MG BASE	N76273	001	Jan 14, 2008	Jan	NEWA

CLOZAPINE

TABLET; ORAL
CLOZAPINE

>D>	AB	TEVA	25MG	N75162	001	Apr 26, 2005	Mar	DISC
>A>		@	25MG	N75162	001	Apr 26, 2005	Mar	DISC
>D>	AB		100MG	N75162	002	Apr 26, 2005	Mar	DISC
>A>		@	100MG	N75162	002	Apr 26, 2005	Mar	DISC

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
TRIACIN-C

	+	ACTAVIS MID ATLANTIC	10MG/5ML;30MG/5ML;1.25MG/5ML	N88704	001	Mar 22, 1985	Feb	CRLD

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

		@ MORTON GROVE	10MG/5ML;30MG/5ML;1.25MG/5ML	N88833	001	Nov 16, 1984	Feb	DISC

COLISTIMETHATE

INJECTABLE; INJECTION
COLISTIMETHATE

>A>	AP	APP PHARMS	EQ 150MG BASE/VIAL	N65364	001	Apr 17, 2008	Mar	NEWA

COSYNTROPIN

SOLUTION; INTRAVENOUS
COSYNTROPIN

		SANDOZ	0.25MG/ML (0.25MG/ML)	N22028	001	Feb 21, 2008	Feb	NEWA

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

>A>	AB	AMNEAL PHARM	10MG	N78218	001	Apr 18, 2008	Mar	NEWA
		@ SANDOZ	10MG	N73683	001	Feb 26, 1993	Feb	DISC
		@ WATSON LABS	10MG	N73143	001	Nov 27, 1991	Feb	DISC
		@	10MG	N74436	001	Nov 30, 1994	Feb	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
CYCLOPHOSPHAMIDE

		@ BAXTER HLTHCARE	100MG/VIAL	N88371	001	Jul 03, 1986	Jan	DISC
		@	200MG/VIAL	N88372	001	Jul 03, 1986	Jan	DISC
		@	500MG/VIAL	N88373	001	Jul 03, 1986	Jan	DISC
		@	1GM/VIAL	N88374	001	Sep 24, 1986	Jan	DISC

	INJECTABLE; INJECTION							
	LYOPHILIZED CYTOXAN							
+	BRISTOL MYERS SQUIBB	100MG/VIAL	N12142	006	Dec 05, 1985	Jan	CTEC
+		200MG/VIAL	N12142	007	Dec 10, 1985	Jan	CTEC
+		500MG/VIAL	N12142	008	Jan 04, 1984	Jan	CTEC
+		1GM/VIAL	N12142	010	Sep 24, 1985	Jan	CTEC
+		2GM/VIAL	N12142	009	Dec 10, 1984	Jan	CTEC
	NEOSAR							
@	TEVA PARENTERAL	100MG/VIAL	N87442	001	Feb 16, 1982	Jan	DISC
@		200MG/VIAL	N87442	002	Feb 16, 1982	Jan	DISC
@		500MG/VIAL	N87442	003	Feb 16, 1982	Jan	DISC
@		1GM/VIAL	N87442	004	Jul 08, 1983	Jan	DISC
@		2GM/VIAL	N87442	005	Mar 30, 1989	Jan	DISC
	TABLET; ORAL							
	CYCLOPHOSPHAMIDE							
	ROXANE	25MG	N40032	001	Aug 17, 1999	Jan	CTEC
+		50MG	N40032	002	Aug 17, 1999	Jan	CRLD
	CYTOXAN							
@	BRISTOL MYERS SQUIBB	25MG	N12141	002		Jan	DISC
@		50MG	N12141	001		Jan	DISC
	DARUNAVIR ETHANOLATE							
	TABLET; ORAL							
	PREZISTA							
	TIBOTEC	EQ 300MG BASE	N21976	001	Jun 23, 2006	Feb	CRLD
+		EQ 600MG BASE	N21976	002	Feb 25, 2008	Feb	NEWA
	DEMECLOCYCLINE HYDROCHLORIDE							
	TABLET; ORAL							
	DEMECLOCYCLINE HYDROCHLORIDE							
AB	AMNEAL PHARM	150MG	N65425	001	Feb 27, 2008	Feb	NEWA
AB		300MG	N65425	002	Feb 27, 2008	Feb	NEWA
	DESVENLAFAXINE SUCCINATE							
	TABLET, EXTENDED RELEASE; ORAL							
	PRISTIQ							
	WYETH PHARMS INC	EQ 50MG BASE	N21992	001	Feb 29, 2008	Feb	NEWA
+		EQ 100MG BASE	N21992	002	Feb 29, 2008	Feb	NEWA
	DEXAMETHASONE							
	ELIXIR; ORAL							
	DEXAMETHASONE							
AA +	MORTON GROVE	0.5MG/5ML	N88254	001	Jul 27, 1983	Feb	CTNA
	DEXCHLORPHENIRAMINE MALEATE							
	SYRUP; ORAL							
	DEXCHLORPHENIRAMINE MALEATE							
+	MORTON GROVE	2MG/5ML	N88251	001	Mar 23, 1984	Feb	CTNA
	TABLET; ORAL							
	DEXCHLORPHENIRAMINE MALEATE							
@	PLIVA	2MG	N88682	001	Jan 17, 1986	Feb	DISC
	DEXTROAMPHETAMINE SULFATE							
	SOLUTION; ORAL							
	DEXTROAMPHETAMINE SULFATE							
+	OUTLOOK PHARMS	5MG/5ML	N40776	001	Jan 29, 2008	Jan	NEWA

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

@	MARSAM PHARMS LLC	5MG/ML	N72397	001	Jan 29, 1993	Feb		DISC

DICLOFENAC SODIUM

GEL; TOPICAL
SOLARAZE

+	NYCOMED US	3%	N21005	001	Oct 16, 2000	Feb		CAHN

SOLUTION/DROPS; OPHTHALMIC
DICLOFENAC SODIUM

>A> AT	AKORN	0.1%	N77845	001	Apr 17, 2008	Mar		NEWA
AT	ALCON	0.1%	N78031	001	Feb 06, 2008	Jan		NEWA

DICLOXACILLIN SODIUM

FOR SUSPENSION; ORAL
DICLOXACILLIN SODIUM

@	APOTHECON	EQ 62.5MG BASE/5ML	N61455	001		Jan		DISC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE

@	HOSPIRA	5MG/ML	N75004	001	Feb 16, 2000	Feb		DISC

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HYDROCHLORIDE

@	MUTUAL PHARM	25MG	N84506	001		Feb		DISC
@		25MG	N89488	001	Jan 02, 1987	Feb		DISC

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB	ZYDUS PHARMS USA INC	25MG	N40874	001	Jan 28, 2008	Jan		NEWA
AB		50MG	N40874	002	Jan 28, 2008	Jan		NEWA
AB		75MG	N40874	003	Jan 28, 2008	Jan		NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

@	MARSAM PHARMS LLC	EQ 12.5MG BASE/ML	N74995	001	Mar 31, 1998	Feb		DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL
ZONALON

+	NYCOMED US	5%	N20126	001	Apr 01, 1994	Feb		CAHN

ECONAZOLE NITRATE

CREAM; TOPICAL
SPECTAZOLE

@	ORTHONEUTROGENA	1%	N18751	001	Dec 23, 1982	Feb		CAHN

EDETATE DISODIUM

INJECTABLE; INJECTION
EDETATE DISODIUM

@	APOTEX INC	150MG/ML	N40376	001	Nov 04, 2002	Jan	DISC	

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION
ENLON

@	BAXTER HLTHCARE CORP	10MG/ML	N88873	001	Aug 06, 1985	Feb	DISC	

ERYTHROMYCIN

SWAB; TOPICAL
ERYCETTE

@	ORTHONEUTROGENA	2%	N50594	001	Feb 15, 1985	Feb	CAHN	

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL
NEXIUM

	ASTRAZENECA	EQ 10MG BASE/PACKET	N22101	001	Feb 27, 2008	Feb	NEWA	

ESTRADIOL

GEL, METERED; TRANSDERMAL
ELESTRIN

+	BRADLEY PHARMS	0.06% (0.87GM/ACTIVATION)	N21813	001	Dec 15, 2006	Jan	CTEC	
+	NYCOMED US	0.06% (0.87GM/ACTIVATION)	N21813	001	Dec 15, 2006	Feb	CAHN	

ESTROGEL

+	ASCEND	0.06% (1.25GM/ACTIVATION)	N21166	002	Feb 09, 2004	Jan	CTEC	

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL
ACTIVELLA

>D>		+	NOVO NORDISK INC	1MG;0.5MG	N20907	001	Nov 18, 1998	Mar	CFTG
>A>	AB	+		1MG;0.5MG	N20907	001	Nov 18, 1998	Mar	CFTG

>A> ESTRADIOL AND NORETHIDRONE ACETATE

>A>	AB		BRECKENRIDGE PHARM	1MG;0.5MG	N78324	001	Apr 17, 2008	Mar	NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET; ORAL
MYAMBUTOL

AB		STAT-TRADE	100MG	N16320	001		Jan	CAHN
	@		200MG	N16320	002		Jan	CAHN
AB			400MG	N16320	003		Jan	CAHN
	@		500MG	N16320	004		Jan	CAHN

ETRAVIRINE

TABLET; ORAL
INTELENCE

+	TIBOTEC	100MG	N22187	001	Jan 18, 2008	Jan	NEWA	

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

@	APOTEX INC	10MG/ML	N75942	001	Aug 02, 2002	Feb	DISC	
@	HOSPIRA	10MG/ML	N75905	001	Nov 23, 2001	Feb	DISC	

TABLET; ORAL
FAMOTIDINE

		@ SANDOZ	20MG	N75793	001	Apr 16, 2001	Feb		DISC
		@	40MG	N75793	002	Apr 16, 2001	Feb		DISC

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
FELODIPINE

>A>	AB	MYLAN	2.5MG	N78855	001	Apr 17, 2008	Mar		NEWA
>A>	AB		5MG	N78855	002	Apr 17, 2008	Mar		NEWA
>A>	AB		10MG	N78855	003	Apr 17, 2008	Mar		NEWA

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE

>A>	AB	IMPAX LABS	54MG	N76509	001	Mar 26, 2008	Mar		NEWA
>A>	AB		160MG	N76509	002	Mar 26, 2008	Mar		NEWA

FENOPROFEN CALCIUM

TABLET; ORAL
FENOPROFEN CALCIUM

		@ WATSON LABS	EQ 600MG BASE	N72407	001	Aug 17, 1988	Feb		DISC
		@	EQ 600MG BASE	N72602	001	Oct 11, 1988	Feb		DISC

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE

>A>	AB	MYLAN	30MG	N77081	002	Apr 11, 2008	Mar		NEWA
>A>	AB		60MG	N77081	003	Apr 11, 2008	Mar		NEWA

FLECAINIDE ACETATE

TABLET; ORAL
FLECAINIDE ACETATE

	AB	AMNEAL PHARM	50MG	N75442	001	Jul 31, 2001	Feb		CAHN
	AB		100MG	N75442	002	Jul 31, 2001	Feb		CAHN
	AB		150MG	N75442	003	Jul 31, 2001	Feb		CAHN

FLUOCINONIDE

CREAM; TOPICAL
FLUOCINONIDE

		@ TARO	0.05%	N71500	001	Jun 10, 1987	Feb		DISC

SOLUTION; TOPICAL
FLUOCINONIDE

		@ TARO	0.05%	N72857	001	Aug 02, 1989	Feb		DISC

FLUOROURACIL

CREAM; TOPICAL
EFUDEX

>D>		+ VALEANT PHARM INTL	5%	N16831	003			Mar	CFTG
>A>	AB	+	5%	N16831	003			Mar	CFTG

>A> FLUOROURACIL

>A>	AB	SPEAR PHARMS	5%	N77524	001	Apr 11, 2008	Mar		NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
FLUOXETINE

AB	AUROBINDO PHARMA	EQ 10MG BASE	N78619	001	Jan 31, 2008	Jan	NEWA
AB		EQ 20MG BASE	N78619	002	Jan 31, 2008	Jan	NEWA
AB		EQ 40MG BASE	N78619	003	Jan 31, 2008	Jan	NEWA
AB	WOCKHARDT	EQ 10MG BASE	N78143	001	Jan 16, 2008	Jan	NEWA
AB		EQ 20MG BASE	N78143	002	Jan 16, 2008	Jan	NEWA
AB		EQ 40MG BASE	N78143	003	Jan 16, 2008	Jan	NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL
FLUTICASONE PROPIONATE

AB	HI TECH PHARMA	0.05MG/SPRAY	N77570	001	Jan 16, 2008	Jan	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL
LUVOX CR

	SOLVAY	100MG	N22033	001	Feb 28, 2008	Feb	NEWA
+		150MG	N22033	002	Feb 28, 2008	Feb	NEWA

FOMEPIZOLE

INJECTABLE; INJECTION
FOMEPIZOLE

AP	NAVINTA LLC	1.5GM/1.5ML (1GM/ML)	N78537	001	Mar 06, 2008	Feb	NEWA
AP	SYNERX PHARMA	1.5GM/1.5ML (1GM/ML)	N78639	001	Mar 03, 2008	Feb	NEWA

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS
EMEND

+	MERCK AND CO INC	EQ 115MG BASE/VIAL	N22023	001	Jan 25, 2008	Jan	NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION
FOSPHENYTOIN SODIUM

>A>	AP	AKORN STRIDES	EQ 50MG PNENYTOIN NA/ML	N78476	001	Mar 18, 2008	Mar	NEWA
>A>	AP	SUN PHARM INDS	EQ 50MG PHENYTOIN NA/ML	N78417	001	Mar 18, 2008	Mar	NEWA

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

	AB	AUROBINDO PHARM	100MG	N78787	001	Jan 31, 2008	Jan	NEWA
	AB		300MG	N78787	002	Jan 31, 2008	Jan	NEWA
	AB		400MG	N78787	003	Jan 31, 2008	Jan	NEWA
>D>	AB	MUTUAL PHARM	100MG	N76537	001	Jun 30, 2005	Mar	DISC
>A>		@	100MG	N76537	001	Jun 30, 2005	Mar	DISC
>D>	AB		300MG	N76537	002	Jun 30, 2005	Mar	DISC
>A>		@	300MG	N76537	002	Jun 30, 2005	Mar	DISC
>D>	AB		400MG	N76537	003	Jun 30, 2005	Mar	DISC
>A>		@	400MG	N76537	003	Jun 30, 2005	Mar	DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	CARACO	2.5MG;250MG	N77620	001	Jan 11, 2008	Jan	NEWA

		TABLET; ORAL						
		GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
	AB	CARACO	2.5MG;500MG	N77620	002	Jan 11, 2008	Jan	NEWA
	AB		5MG;500MG	N77620	003	Jan 11, 2008	Jan	NEWA
		GLUTAMINE						
		FOR SOLUTION; ORAL						
		NUTRESTORE						
>D>		@ NUTRITIONAL RESTART	5GM/PACKET	N21667	001	Jun 10, 2004	Mar	CMFD
>A>		+	5GM/PACKET	N21667	001	Jun 10, 2004	Mar	CMFD
		GLYCOPYRROLATE						
		TABLET; ORAL						
		GLYCOPYRROLATE						
>A>	AA	INDICUS PHARMA	1MG	N40847	001	Mar 21, 2008	Mar	NEWA
>A>	AA		2MG	N40847	002	Mar 21, 2008	Mar	NEWA
		GRANISETRON HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		GRANISETRON HYDROCHLORIDE						
	AP	WOCKHARDT USA	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	N78566	001	Feb 29, 2008	Feb	NEWA
		SOLUTION; ORAL						
		GRANISETRON HYDROCHLORIDE						
	AA	CYPRESS PHARM	EQ 2MG BASE/10ML	N78334	001	Feb 28, 2008	Feb	NEWA
		KYTRIL						
	AA	+ ROCHE	EQ 2MG BASE/10ML	N21238	001	Jun 27, 2001	Feb	CFTG
		TABLET; ORAL						
		GRANISETRON HYDROCHLORIDE						
	AB	APOTEX INC	EQ 1MG BASE	N78843	001	Feb 27, 2008	Feb	NEWA
	AB	CIPLA LTD	EQ 1MG BASE	N78037	001	Feb 27, 2008	Feb	NEWA
	AB	MYLAN	EQ 1MG BASE	N78725	001	Jan 30, 2008	Jan	NEWA
	AB	ORCHID HLTHCARE	EQ 1MG BASE	N78678	001	Feb 13, 2008	Jan	NEWA
		GRISEOFULVIN, MICROCRYSTALLINE						
		SUSPENSION; ORAL						
		GRIFULVIN V						
	AB	+ ORTHONEUTROGENA	125MG/5ML	N62483	001	Jan 26, 1984	Feb	CAHN
		TABLET; ORAL						
>D>		FULVICIN-U/F						
>D>	AB	+ SCHERING	250MG	N60569	002		Mar	DISC
>A>		@	250MG	N60569	002		Mar	DISC
>D>	AB	+	500MG	N60569	001		Mar	DISC
>A>		@	500MG	N60569	001		Mar	DISC
		GRIFULVIN V						
		ORTHONEUTROGENA	125MG	N62279	001		Feb	CAHN
>D>	AB		250MG	N62279	002		Mar	CRLD
>A>		+	250MG	N62279	002		Mar	CRLD
	AB		250MG	N62279	002		Feb	CAHN
>D>	AB		500MG	N62279	003		Mar	CRLD
>A>		+	500MG	N62279	003		Mar	CRLD
	AB		500MG	N62279	003		Feb	CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL
GUANFACINE HYDROCHLORIDE

AB	AMNEAL PHARM	EQ 1MG BASE	N75109	001	Nov 25, 1998	Feb	CAHN
AB		EQ 2MG BASE	N75109	002	Nov 25, 1998	Feb	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM PRESERVATIVE FREE

+	HOSPIRA	2,500 UNITS/ML	N05264	014	Apr 07, 1986	Jan	CTEC

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	HI TECH PHARMA	1.5MG/5ML;5MG/5ML	N40613	001	Feb 08, 2008	Jan	NEWA
AA	MORTON GROVE	1.5MG/5ML;5MG/5ML	N88008	001	Mar 03, 1983	Feb	CTNA

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

@	MUTUAL PHARM	10MG	N89359	001	Jul 25, 1986	Feb	DISC
@		25MG	N89258	001	May 05, 1986	Feb	DISC
@		50MG	N89259	001	May 05, 1986	Feb	DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB	CADISTA PHARMS	12.5MG	N78391	001	Feb 11, 2008	Jan	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL
HYDROXYCHLOROQUINE SULFATE

AB	IPCA LABS LTD	200MG	N40766	001	Jun 14, 2007	Jan	CMFD

HYDROXYUREA

TABLET; ORAL
HYDROXYUREA

@	BARR	1GM	N75734	001	Aug 29, 2000	Jan	DISC

>D> HYDROXYZINE

>D> TABLET; ORAL
>D> HYDROXYZINE HYDROCHLORIDE

>D> AB	INVAGEN PHARMS	10MG	N40812	001	Mar 12, 2008	Mar	CAIN
AB		10MG	N40812	001	Mar 12, 2008	Feb	NEWA
>D> AB		25MG	N40812	002	Mar 12, 2008	Mar	CAIN
AB		25MG	N40812	002	Mar 12, 2008	Feb	NEWA
>D> AB		50MG	N40812	003	Mar 12, 2008	Mar	CAIN
AB		50MG	N40812	003	Mar 12, 2008	Feb	NEWA

>A> HYDROXYZINE HYDROCHLORIDE

>A> TABLET; ORAL
>A> HYDROXYZINE HYDROCHLORIDE

>A> AB	INVAGEN PHARMS	10MG	N40812	001	Mar 12, 2008	Mar	CAIN
>A> AB		25MG	N40812	002	Mar 12, 2008	Mar	CAIN

>A>		TABLET; ORAL								
>A>		HYDROXYZINE HYDROCHLORIDE								
>A>	AB	INVAGEN PHARMS	50MG	N40812	003	Mar 12, 2008	Mar	CAIN		
>A>	AB	NORTHSTAR HLTHCARE	10MG	N40841	001	Mar 31, 2008	Mar	NEWA		
>A>	AB		25MG	N40842	001	Mar 31, 2008	Mar	NEWA		
>A>	AB		50MG	N40840	001	Mar 31, 2008	Mar	NEWA		
		IMIPRAMINE HYDROCHLORIDE								
		TABLET; ORAL								
		IMIPRAMINE HYDROCHLORIDE								
	AB	ACTAVIS TOTOWA	10MG	N40753	001	Feb 28, 2008	Feb	NEWA		
	AB		25MG	N40752	001	Feb 28, 2008	Feb	NEWA		
	AB		50MG	N40751	001	Feb 28, 2008	Feb	NEWA		
		IMIPRAMINE PAMOATE								
		CAPSULE; ORAL								
		TOFRANIL-PM								
	+	TYCO HLTHCARE	EQ 75MG HCL	N17090	001		Jan	CRLD		
			EQ 150MG HCL	N17090	002		Jan	CRLD		
		INDAPAMIDE								
		TABLET; ORAL								
		INDAPAMIDE								
>D>	AB	MYLAN	2.5MG	N74461	001	Mar 27, 1996	Mar	CRLD		
>A>	AB	+	2.5MG	N74461	001	Mar 27, 1996	Mar	CRLD		
		LOZOL								
>D>	AB	SANOFI AVENTIS US	1.25MG	N18538	002	Apr 29, 1993	Mar	DISC		
>A>		@	1.25MG	N18538	002	Apr 29, 1993	Mar	DISC		
>D>	AB	+	2.5MG	N18538	001	Jul 06, 1983	Mar	DISC		
>A>		@	2.5MG	N18538	001	Jul 06, 1983	Mar	DISC		
		INDOMETHACIN								
		CAPSULE; ORAL								
		INDOCIN								
		@ IROKO PHARMS	25MG	N16059	001		Feb	CAHN		
		@	50MG	N16059	002		Feb	CAHN		
		INDOMETHACIN								
	AB	IVAX PHARMS	25MG	N70719	001	Feb 12, 1986	Jan	CMFD		
	AB		50MG	N70756	001	Feb 12, 1986	Jan	CMFD		
		CAPSULE, EXTENDED RELEASE; ORAL								
		INDOCIN SR								
		@ IROKO PHARMS	75MG	N18185	001	Feb 23, 1982	Feb	CAHN		
		SUPPOSITORY; RECTAL								
		INDOCIN								
		@ IROKO PHARMS	50MG	N17814	001	Aug 13, 1984	Feb	CAHN		
		IRINOTECAN HYDROCHLORIDE								
		INJECTABLE; INJECTION								
		CAMPTOSAR								
	AP	+ PFIZER INC	40MG/2ML (20MG/ML)	N20571	001	Jun 14, 1996	Feb	CFTG		
	AP	+	100MG/5ML (20MG/ML)	N20571	002	Jun 14, 1996	Feb	CFTG		
		IRINOTECAN HYDROCHLORIDE								
	AP	ACTAVIS TOTOWA	40MG/2ML (20MG/ML)	N78589	001	Feb 27, 2008	Feb	NEWA		
	AP		100MG/5ML (20MG/ML)	N78589	002	Feb 27, 2008	Feb	NEWA		
	AP	APP PHARMS	40MG/2ML (20MG/ML)	N77776	001	Feb 27, 2008	Feb	NEWA		
	AP		100MG/5ML (20MG/ML)	N77776	002	Feb 27, 2008	Feb	NEWA		

INJECTABLE; INJECTION
IRINOTECAN HYDROCHLORIDE

	AP	DABUR ONCOLOGY PLC	40MG/2ML (20MG/ML)	N78188	001	Feb 27, 2008	Feb	NEWA
	AP		100MG/5ML (20MG/ML)	N78188	002	Feb 27, 2008	Feb	NEWA
	AP	HOSPIRA	40MG/2ML (20MG/ML)	N77915	001	Feb 27, 2008	Feb	NEWA
	AP		100MG/5ML (20MG/ML)	N77915	002	Feb 27, 2008	Feb	NEWA
	+		500MG/25ML (20MG/ML)	N78796	001	Feb 27, 2008	Feb	NEWA
	AP	SANDOZ	40MG/2ML (20MG/ML)	N77994	001	Feb 27, 2008	Feb	NEWA
	AP		100MG/5ML (20MG/ML)	N77994	002	Feb 27, 2008	Feb	NEWA
	AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	N77260	001	Feb 27, 2008	Feb	NEWA
	AP		100MG/5ML (20MG/ML)	N77260	002	Feb 27, 2008	Feb	NEWA
	AP	WATSON LABS	40MG/2ML (20MG/ML)	N77219	001	Feb 20, 2008	Feb	NEWA
	AP		100MG/5ML (20MG/ML)	N77219	002	Feb 20, 2008	Feb	NEWA

ISONIAZID

TABLET; ORAL
ISONIAZID

>D>	AA	MUTUAL PHARM	300MG	N83633	001		Mar	DISC
>A>		@	300MG	N83633	001		Mar	DISC

ISOSORBIDE DINITRATE

TABLET; SUBLINGUAL
ISOSORBIDE DINITRATE

	AB	+ WATSON LABS	5MG	N86031	001	Sep 29, 1987	Jan	CRLD

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE DINITRATE

>A>	AB	COREPHARMA	40MG	N40723	001	Mar 17, 2008	Mar	NEWA
>D>		+ INWOOD LABS	40MG	N40009	001	Dec 30, 1998	Mar	CTEC
>A>	AB	+	40MG	N40009	001	Dec 30, 1998	Mar	CTEC

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

	AP	LUITPOLD	15MG/ML	N78145	001	Jan 14, 2008	Jan	NEWA
	AP		30MG/ML	N78145	002	Jan 14, 2008	Jan	NEWA

LEUPROLIDE ACETATE

IMPLANT; IMPLANTATION
VIADUR

	+	JOHNSON AND JOHNSON	EQ 65MG BASE	N21088	001	Mar 03, 2000	Feb	CAHN

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION
>A> LEVALBUTEROL HYDROCHLORIDE

>A>	AN	BREATH LTD	EQ 0.0103% BASE	N77756	003	Apr 09, 2008	Mar	NEWA
>A>	AN		EQ 0.021% BASE	N77756	001	Apr 09, 2008	Mar	NEWA
>A>	AN		EQ 0.042% BASE	N77756	002	Apr 09, 2008	Mar	NEWA

XOPENEX

>D>		+ SEPRACOR	EQ 0.0103% BASE	N20837	003	Jan 30, 2002	Mar	CFTG
>A>	AN	+	EQ 0.0103% BASE	N20837	003	Jan 30, 2002	Mar	CFTG
>D>		+	EQ 0.021% BASE	N20837	001	Mar 25, 1999	Mar	CFTG
>A>	AN	+	EQ 0.021% BASE	N20837	001	Mar 25, 1999	Mar	CFTG
>D>		+	EQ 0.042% BASE	N20837	002	Mar 25, 1999	Mar	CFTG
>A>	AN	+	EQ 0.042% BASE	N20837	002	Mar 25, 1999	Mar	CFTG

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION; ORAL
XYZAL

+	UCB INC	2.5MG/5ML	N22157	001	Jan 28, 2008	Jan	NEWA

LEVOLEUCOVORIN CALCIUM

POWDER; IV (INFUSION)
LEVOLEUCOVORIN

+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N20140	001	Mar 07, 2008	Mar	NEWA

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN

AP	+	DENTSPLY PHARM	0.05MG/ML;2%	N89517	001	Apr 14, 1988	Jan	CRLD

LEVOTHYROXINE SODIUM**

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information

TABLET; ORAL
LEVOXYL

AB1, AB3	+	KING PHARMS	0.2MG	N21301	011	May 25, 2001	Jan	CRLD
	@		0.3MG	N21301	012	May 25, 2001	Jan	DISC

UNITHROID

AB1, AB2, AB3		STEVENS J	0.137MG	N21210	012	Feb 08, 2008	Feb	NEWA

LITHIUM CARBONATE

CAPSULE; ORAL
ESKALITH

AB		NOVEN THERAP	300MG	N16860	001		Jan	CAHN

LITHIUM CARBONATE

>D>	+	ROXANE	600MG	N17812	003	Jan 28, 1987	Mar	CTEC
>A> AB	+		600MG	N17812	003	Jan 28, 1987	Mar	CTEC
>A> AB		WEST WARD	600MG	N78763	001	Apr 15, 2008	Mar	NEWA

TABLET, EXTENDED RELEASE; ORAL
LITHOBID

AB	+	NOVEN THERAP	300MG	N18027	001		Jan	CAHN

LOVASTATIN

TABLET; ORAL
LOVASTATIN

>A> AB		LUPIN	10MG	N78296	001	Mar 14, 2008	Mar	NEWA

MELOXICAM

TABLET; ORAL
MELOXICAM

@ ROXANE			7.5MG	N77925	001	Jul 19, 2006	Feb	DISC
@			15MG	N77925	002	Jul 19, 2006	Feb	DISC

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA		INVAGEN PHARMS	200MG	N40797	001	Feb 27, 2008	Feb	NEWA
AA			400MG	N40797	002	Feb 27, 2008	Feb	NEWA
AA	+	WATSON LABS	400MG	N83308	001		Feb	CTEC

METAPROTERENOL SULFATE

SYRUP; ORAL
METAPROTERENOL SULFATE

		@	MORTON GROVE	10MG/5ML	N74702	001	Mar 24, 1997	Feb	DISC
	AA	+	SILARX	10MG/5ML	N73632	001	Jul 22, 1992	Feb	CRLD

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>A>	AB		NEUROSCI INC	500MG	N78321	001	Apr 17, 2008	Mar	NEWA
>A>	AB			750MG	N78321	002	Apr 17, 2008	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL
PAMINE

	AA	+	NYCOMED US	2.5MG	N08848	001		Feb	CAHN

PAMINE FORTE

	AA	+	NYCOMED US	5MG	N08848	002	Mar 25, 2003	Feb	CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL
METOCLOPRAMIDE HYDROCHLORIDE

	AA	+	MORTON GROVE	EQ 5MG BASE/5ML	N74703	001	Oct 31, 1997	Feb	CAHN

TABLET; ORAL
REGLAN

>A>	AB		ALAVEN PHARM	EQ 5MG BASE	N17854	002	May 05, 1987	Mar	CAHN
>A>	AB	+		EQ 10MG BASE	N17854	001		Mar	CAHN
>D>	AB		SCHWARZ PHARMA	EQ 5MG BASE	N17854	002	May 05, 1987	Mar	CAHN
>D>	AB	+		EQ 10MG BASE	N17854	001		Mar	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
REGLAN ODT

>A>		@	ALAVEN PHARM	EQ 5MG BASE	N21793	001	Jun 10, 2005	Mar	CAHN
>A>		@		EQ 10MG BASE	N21793	002	Jun 10, 2005	Mar	CAHN
>D>		@	SCHWARZ PHARMA	EQ 5MG BASE	N21793	001	Jun 10, 2005	Mar	CAHN
>D>		@		EQ 10MG BASE	N21793	002	Jun 10, 2005	Mar	CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
METOPROLOL SUCCINATE

>A>	AB		KV PHARM	EQ 25MG TARTRATE	N77779	001	Mar 20, 2008	Mar	NEWA
>A>	AB		SANDOZ	EQ 100MG TARTRATE	N76969	003	Mar 20, 2008	Mar	NEWA
>A>	AB			EQ 200MG TARTRATE	N76969	004	Mar 20, 2008	Mar	NEWA

METRONIDAZOLE

INJECTABLE; INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER

>A>	AP		CLARIS LIFESCIENCES	500MG/100ML	N78084	001	Mar 31, 2008	Mar	NEWA

MICONAZOLE NITRATE

CREAM; TOPICAL
MONISTAT-DERM

		+	ORTHONEUTROGENA	2%	N17494	001		Feb	CAHN

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA	EQ 50MG BASE	N65470	001	Mar 11, 2008	Feb	NEWA
AB		EQ 75MG BASE	N65470	002	Mar 11, 2008	Feb	NEWA
AB		EQ 100MG BASE	N65470	003	Mar 11, 2008	Feb	NEWA
AB	TEVA	EQ 100MG BASE	N63009	001	Mar 02, 1992	Feb	CRLD

TABLET; ORAL
MINOCYCLINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	EQ 50MG BASE	N65436	001	Dec 26, 2007	Feb	CAHN
AB		EQ 75MG BASE	N65436	002	Dec 26, 2007	Feb	CAHN
AB		EQ 100MG BASE	N65436	003	Dec 26, 2007	Feb	CAHN

MINOXIDIL

TABLET; ORAL
LONITEN

@	PHARMACIA AND UPJOHN	2.5MG	N18154	001		Jan	DISC
@		10MG	N18154	003		Jan	DISC

MINOXIDIL

>D>	AB	WATSON LABS	10MG	N71345	001	Mar 03, 1987	Mar	CRLD
>A>	AB	+	10MG	N71345	001	Mar 03, 1987	Mar	CRLD

MOMETASONE FUROATE

POWDER; INHALATION
ASMANEX TWISTHALER

SCHERING	0.11MG/INH	N21067	002	Feb 01, 2008	Feb	NEWA

MORPHINE SULFATE

>A> SOLUTION; ORAL
>A> MORPHINE SULFATE

>A> ROXANE	10MG/5ML	N22195	001	Mar 17, 2008	Mar	NEWA
>A> +	20MG/5ML	N22195	002	Mar 17, 2008	Mar	NEWA

>A> TABLET; ORAL
>A> MORPHINE SULFATE

>A> ROXANE	15MG	N22207	001	Mar 17, 2008	Mar	NEWA
>A> +	30MG	N22207	002	Mar 17, 2008	Mar	NEWA

MUPIROCIN

OINTMENT; TOPICAL
CENTANY

BX	ORTHONEUTROGENA	2%	N50788	001	Dec 04, 2002	Feb	CAHN

NABUMETONE

TABLET; ORAL
NABUMETONE

AB	INVAGEN PHARMS	500MG	N78671	001	Mar 07, 2008	Feb	NEWA
AB		750MG	N78671	002	Mar 07, 2008	Feb	NEWA

NIACIN; SIMVASTATIN

TABLET, EXTENDED RELEASE; ORAL
SIMCOR

ABBOTT	500MG;20MG	N22078	001	Feb 15, 2008	Feb	NEWA
	750MG;20MG	N22078	002	Feb 15, 2008	Feb	NEWA
+	1GM;20MG	N22078	003	Feb 15, 2008	Feb	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL
NICARDIPINE HYDROCHLORIDE

AB		AMNEAL PHARM	20MG	N74928	001	Mar 19, 1998	Feb	CAHN
AB			30MG	N74928	002	Mar 19, 1998	Feb	CAHN

NIMODIPINE

CAPSULE; ORAL
NIMODIPINE

AB		BANNER PHARMACAPS	30MG	N76740	001	Jan 17, 2008	Jan	NEWA

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
SULAR

	+	SCIELE PHARMA INC	8.5MG	N20356	008	Jan 02, 2008	Jan	NEWA
	+		17MG	N20356	007	Jan 02, 2008	Jan	NEWA
			25.5MG	N20356	006	Jan 02, 2008	Jan	NEWA
	+		34MG	N20356	005	Jan 02, 2008	Jan	NEWA

NITROFURAZONE

OINTMENT; TOPICAL
NITROFURAZONE

		@ TARO	0.2%	N86156	001		Jan	DISC

NYSTATIN

TABLET; ORAL
NYSTATIN

AA	+	TEVA	500,000 UNITS	N62506	001	Jan 16, 1984	Jan	CRLD

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
OCTREOTIDE ACETATE

AP	+	BEDFORD	EQ 0.2MG BASE/ML	N76330	001	Apr 08, 2005	Jan	CRLD
AP	+		EQ 1MG BASE/ML	N76330	002	Apr 08, 2005	Jan	CRLD
AP		SUN PHARM INDS	EQ 0.05MG BASE/ML	N77329	001	Mar 04, 2008	Feb	NEWA
AP			EQ 0.1MG BASE/ML	N77329	002	Mar 04, 2008	Feb	NEWA
AP			EQ 0.2MG BASE/ML	N77330	001	Mar 04, 2008	Feb	NEWA
AP			EQ 0.5MG BASE/ML	N77329	003	Mar 04, 2008	Feb	NEWA
AP			EQ 1MG BASE/ML	N77331	001	Mar 04, 2008	Feb	NEWA

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

>A>	AT	AKORN	0.3%	N76407	001	Apr 15, 2008	Mar	NEWA

SOLUTION/DROPS; OTIC
OFLOXACIN

>A>	AT	ALCON	0.3%	N78222	001	Mar 17, 2008	Mar	NEWA
>A>	AT	BAUSCH AND LOMB	0.3%	N76128	001	Mar 17, 2008	Mar	NEWA
>A>	AT	HI TECH PHARMA	0.3%	N76616	001	Mar 17, 2008	Mar	NEWA

>A> OMEPRAZOLE MAGNESIUM

>A> FOR SUSPENSION, DELAYED RELEASE; ORAL
>A> PRILOSEC

>A>		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N22056	001	Mar 20, 2008	Mar	NEWA
>A>	+		EQ 10MG BASE/PACKET	N22056	002	Mar 20, 2008	Mar	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

>A>	AP	CLARIS LIFESCIENCES	EQ 0.64MG BASE/ML	N78308	001	Mar 17, 2008	Mar	NEWA

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>A>	AP	TARO PHARMS IRELAND	EQ 2MG BASE/ML	N78014	001	Mar 21, 2008	Mar	NEWA

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>A>	AB	APOTEX INC	150MG	N77747	001	Apr 09, 2008	Mar	NEWA
>A>	AB		300MG	N77747	002	Apr 09, 2008	Mar	NEWA
>A>	AB		600MG	N77747	003	Apr 09, 2008	Mar	NEWA

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OXYCODONE HYDROCHLORIDE

		@ IMPAX LABS	80MG	N76318	001	Sep 27, 2004	Feb	DISC
		@ IMPAX PHARMS	10MG	N76446	001	Dec 06, 2005	Feb	DISC
		@	20MG	N76446	002	Dec 06, 2005	Feb	DISC
		@	40MG	N76446	003	Dec 06, 2005	Feb	DISC
		@ TEVA	10MG	N76610	001	Dec 06, 2005	Feb	DISC
		@	20MG	N76610	002	Dec 06, 2005	Feb	DISC
		@	40MG	N76610	003	Dec 06, 2005	Feb	DISC
		@	80MG	N76168	001	Mar 23, 2004	Feb	DISC

OXYCONTIN

		PURDUE PHARMA LP	10MG	N20553	001	Dec 12, 1995	Feb	CTEC
			15MG	N20553	006	Sep 18, 2006	Jan	CMFD
			20MG	N20553	002	Dec 12, 1995	Feb	CTEC
			30MG	N20553	007	Sep 18, 2006	Jan	CMFD
	+		40MG	N20553	003	Dec 12, 1995	Feb	CTEC
			60MG	N20553	008	Sep 18, 2006	Jan	CMFD
			80MG	N20553	004	Jan 06, 1997	Feb	CTEC

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

		ENDO PHARMS	7.5MG	N21610	005	Feb 29, 2008	Feb	NEWA
			15MG	N21610	006	Feb 29, 2008	Feb	NEWA
			30MG	N21610	007	Feb 29, 2008	Feb	NEWA

>D> OXYTETRACYCLINE HYDROCHLORIDE

>D> CAPSULE; ORAL

>D> TERRAMYCIN

>D>	+	PFIZER	EQ 250MG BASE	N50286	002		Mar	DISC
>A>		@	EQ 250MG BASE	N50286	002		Mar	DISC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

	AP	+ APP PHARMS	100USP UNITS/10 ML (10USP UNITS/ML)	N18248	002		Jan	CFTG
>A>	AP	+ BAXTER HLTHCARE CORP	100USP UNITS/10ML (10USP UNITS/ML)	N18243	002	Jan 10, 2007	Mar	CDFR
	AP	TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)	N77453	001	Jan 24, 2008	Jan	NEWA

INJECTABLE; INJECTION

OXYTOCIN

	AP		TEVA PARENTERAL	100USP UNITS/10ML (10USP UNITS/ML)	N77453	002	Jan 24, 2008	Jan	NEWA
>D>			INJECTABLE; INTRAMUSCULAR, IV (INFUSION)						
>D>			OXYTOCIN						
>D>	AP	+	BAXTER HLTHCARE CORP	100USP UNITS/10ML (10USP UNITS/ML)	N18243	002	Jan 10, 2007	Mar	CDFR
	AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N18243	002	Jan 10, 2007	Feb	NEWA

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

	AP		PLIVA LACHEMA	6MG/ML	N77413	001	Mar 12, 2008	Feb	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE; ORAL

INVEGA

		+	JANSSEN LP	6MG	N21999	002	Dec 19, 2006	Jan	CRLD
				9MG	N21999	003	Dec 19, 2006	Jan	CRLD

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

ALOXI

			HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N21372	002	Feb 29, 2008	Feb	NEWA
		+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N21372	001	Jul 25, 2003	Feb	CPOT

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

>A>	AB		MYLAN	EQ 10MG BASE	N78902	001	Mar 13, 2008	Mar	NEWA
>A>	AB			EQ 20MG BASE	N78902	002	Mar 13, 2008	Mar	NEWA
>A>	AB			EQ 30MG BASE	N78902	003	Mar 13, 2008	Mar	NEWA
>A>	AB			EQ 40MG BASE	N78902	004	Mar 13, 2008	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

>A>	AA		ACTAVIS TOTOWA	35MG	N40762	001	Jan 28, 2008	Mar	CAHN
>D>	AA		AMIDE PHARM	35MG	N40762	001	Jan 28, 2008	Mar	CAHN
	AA			35MG	N40762	001	Jan 28, 2008	Jan	NEWA

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA		KVK TECH	15MG	N40886	002	Mar 31, 2008	Mar	NEWA
>A>	AA			30MG	N40875	001	Mar 21, 2008	Mar	NEWA
>A>	AA			30MG	N40886	001	Mar 31, 2008	Mar	NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA		KVK TECH	37.5MG	N40876	001	Mar 31, 2008	Mar	NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL
EXTENDED PHENYTOIN SODIUM

	AB		WOCKHARDT USA	100MG EXTENDED	N40732	001	Jan 30, 2008	Jan	NEWA

INJECTABLE; INJECTION
PHENYTOIN SODIUM

>A>	AP	+	BAXTER	50MG/ML	N84307	001		Mar	CAHN
>D>	AP	+	ELKINS SINN	50MG/ML	N84307	001		Mar	CAHN

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

	AB		SCHERING	10MEQ	N19439	002	Jun 13, 1986	Jan	CTNA
	AB	+		20MEQ	N19439	001	Jun 13, 1986	Jan	CTNA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL
MIRAPEX

	AB		BOEHRINGER INGELHEIM	0.125MG	N20667	001	Jul 01, 1997	Feb	CFTG
	AB	+		0.25MG	N20667	002	Jul 01, 1997	Feb	CFTG
	AB			0.5MG	N20667	006	Feb 12, 1998	Feb	CFTG
	AB			1MG	N20667	003	Jul 01, 1997	Feb	CFTG
	AB			1.5MG	N20667	005	Jul 01, 1997	Feb	CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

	AB		BARR	0.125MG	N77724	001	Feb 19, 2008	Feb	NEWA
	AB			0.25MG	N77724	002	Feb 19, 2008	Feb	NEWA
	AB			0.5MG	N77724	003	Feb 19, 2008	Feb	NEWA
	AB			1MG	N77724	004	Feb 19, 2008	Feb	NEWA
	AB			1.5MG	N77724	005	Feb 19, 2008	Feb	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVASTATIN SODIUM

	AB		LEK PHARMS DD	80MG	N77491	001	Feb 11, 2008	Jan	NEWA
	AB		TEVA PHARMS	80MG	N77793	001	Jan 15, 2008	Jan	NEWA

PREDNISOLONE ACETATE

SUSPENSION; ORAL
FLO-PRED

			TARO	EQ 5MG BASE/5ML	N22067	001	Jan 17, 2008	Jan	NEWA
		+		EQ 15MG BASE/5ML	N22067	002	Jan 17, 2008	Jan	NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

	AA		PHARM ASSOC	EQ 10MG BASE/5ML	N78465	001	Mar 07, 2008	Feb	NEWA

PRIMIDONE

TABLET; ORAL
PRIMIDONE

	AB		IMPAX LABS	50MG	N40717	001	Feb 12, 2008	Jan	NEWA
	AB			250MG	N40717	002	Feb 12, 2008	Jan	NEWA

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

	@ TEVA PARENTERAL	EQ 5MG BASE/ML	N40505	001	May 30, 2003	Jan	DISC

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PHENERGAN

	@ WYETH PHARMS INC	25MG	N07935	003		Feb	DISC

PROMETHAZINE HYDROCHLORIDE

AB	ACTAVIS TOTOWA	12.5MG	N40673	001	Mar 05, 2008	Feb	NEWA
AB		25MG	N40673	002	Mar 05, 2008	Feb	NEWA
AB		50MG	N40673	003	Mar 05, 2008	Feb	NEWA
AB	IMPAX LABS	12.5MG	N40724	001	Feb 12, 2008	Jan	NEWA
AB		25MG	N40724	002	Feb 12, 2008	Jan	NEWA

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
PROPRANOLOL HYDROCHLORIDE

AP	HIKMA FARMACEUTICA	1MG/ML	N77760	001	Jan 31, 2008	Jan	NEWA

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL
SEROQUEL XR

>D>	ASTRAZENECA	EQ 200MG BASE	N22047	002	May 17, 2007	Mar	CRLD
>A>	+	EQ 200MG BASE	N22047	002	May 17, 2007	Mar	CRLD
>D>	+	EQ 400MG BASE	N22047	004	May 17, 2007	Mar	CRLD
>A>		EQ 400MG BASE	N22047	004	May 17, 2007	Mar	CRLD

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

>A> AB	LANNETT	150MG	N65390	001	Mar 28, 2008	Mar	NEWA
>A> AB		300MG	N65390	002	Mar 28, 2008	Mar	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL
ERTACZO

+	ORTHONEUTROGENA	2%	N21385	001	Dec 10, 2003	Feb	CAHN

SERTRALINE HYDROCHLORIDE

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

AB	MATRIX LABS LTD	EQ 25MG BASE	N78626	001	Jan 31, 2008	Jan	NEWA
AB		EQ 50MG BASE	N78626	002	Jan 31, 2008	Jan	NEWA
AB		EQ 100MG BASE	N78626	003	Jan 31, 2008	Jan	NEWA

SIMVASTATIN

TABLET; ORAL
SIMVASTATIN

AB	ACCORD HLTHCARE	10MG	N78155	002	Feb 26, 2008	Feb	NEWA
AB		20MG	N78155	003	Feb 26, 2008	Feb	NEWA
AB		40MG	N78155	004	Feb 26, 2008	Feb	NEWA
AB		80MG	N78155	001	Feb 26, 2008	Feb	NEWA

SODIUM IODIDE, I-131

CAPSULE; ORAL

HICON

		DRAXIMAGE	100uCi	N21305	004	Nov 18, 2004	Feb	CTNA

SOLUTION; ORAL

HICON

	+	DRAXIMAGE	1-250mCi/0.25ML	N21305	002	Jan 24, 2003	Feb	CTNA
	+		1-500mCi/0.5ML	N21305	003	Jan 24, 2003	Feb	CTNA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

ACCRETROPIN

	+	CANGENE	5MG/ML (5MG/ML)	N21538	001	Jan 23, 2008	Jan	NEWA

NORDITROPIN

BX		NOVO NORDISK INC	5MG/1.5ML	N21148	001	Jun 20, 2000	Jan	CTEC

NORDITROPIN NORDIFLEX

BX		NOVO NORDISK INC	5MG/1.5ML	N21148	004	Oct 01, 2004	Jan	CTEC

NUTROPIN AQ

	+	GENENTECH	5MG/2ML (2.5MG/ML)	N20522	003	Jan 03, 2008	Jan	NEWA
	+		10MG/2ML (5MG/ML)	N20522	001	Dec 29, 1995	Jan	CPOT
	+		20MG/2ML (10MG/ML)	N20522	004	Jan 03, 2008	Jan	NEWA

NUTROPIN AQ PEN

	+	GENENTECH	10MG/2ML (5MG/ML)	N20522	002	Apr 22, 2002	Jan	CPOT

OMNITROPE

BX		SANDOZ	5MG/1.5ML	N21426	003	Jan 16, 2008	Jan	NEWA

TEV-TROPIN

BX	+	FERRING	5MG/VIAL	N19774	002	Jan 04, 2002	Jan	CPOT

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

	+	EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N20604	005	Feb 11, 2005	Feb	CMFD

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

	AB2	AMNEAL PHARM	80MG	N77070	001	Nov 04, 2005	Feb	CAHN
	AB2		120MG	N77070	002	Nov 04, 2005	Feb	CAHN
	AB2		160MG	N77070	003	Nov 04, 2005	Feb	CAHN
>D>	AB2	MUTUAL PHARM	80MG	N76576	001	Apr 08, 2004	Mar	DISC
>A>		@	80MG	N76576	001	Apr 08, 2004	Mar	DISC
>D>	AB2		120MG	N76576	002	Apr 08, 2004	Mar	DISC
>A>		@	120MG	N76576	002	Apr 08, 2004	Mar	DISC
>D>	AB2		160MG	N76576	003	Apr 08, 2004	Mar	DISC
>A>		@	160MG	N76576	003	Apr 08, 2004	Mar	DISC

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

>D>	AB	MUTUAL PHARM	25MG	N87265	001		Mar	DISC
>A>		@	25MG	N87265	001		Mar	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AP	BAXTER HLTHCARE	80MG/ML;16MG/ML	N70628	001	Dec 29, 1987	Mar	DISC
>A>		@	80MG/ML;16MG/ML	N70628	001	Dec 29, 1987	Mar	DISC

INJECTABLE; INJECTION
SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	AP		HOSPIRA	80MG/ML;16MG/ML	N73199	001	Sep 11, 1992	Mar	DISC
>A>		@		80MG/ML;16MG/ML	N73199	001	Sep 11, 1992	Mar	DISC
>D>	AP		TEVA PARENTERAL	80MG/ML;16MG/ML	N73303	001	Oct 31, 1991	Mar	CRLD
>A>		+		80MG/ML;16MG/ML	N73303	001	Oct 31, 1991	Mar	CRLD

SULFASALAZINE

TABLET; ORAL
SULFASALAZINE

>D>	AB		MUTUAL PHARM	500MG	N89590	001	Oct 19, 1987	Mar	DISC
>A>		@		500MG	N89590	001	Oct 19, 1987	Mar	DISC

TADALAFIL

TABLET; ORAL
CIALIS

			LILLY	2.5MG	N21368	004	Jan 07, 2008	Jan	NEWA

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE; INJECTION
CHOLETEC

	AP	+	BRACCO	N/A	N18963	001	Jan 21, 1987	Jan	CFTG

TECHNETIUM TC-99M MEBROFENIN

	AP		CIS	N/A	N78242	001	Jan 29, 2008	Jan	NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
DRAXIMAGE MDP-25

>D>		+	DRAXIMAGE	N/A	N18035	002	Feb 27, 2004	Mar	CTEC
>A>	AP	+		N/A	N18035	002	Feb 27, 2004	Mar	CTEC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL
TERAZOSIN HYDROCHLORIDE

		@	MYLAN TECHNOLOGIES	EQ 1MG BASE	N75384	001	Dec 01, 2000	Feb	DISC
		@		EQ 2MG BASE	N75384	002	Dec 01, 2000	Feb	DISC
		@		EQ 5MG BASE	N75384	003	Dec 01, 2000	Feb	DISC
		@		EQ 10MG BASE	N75384	004	Dec 01, 2000	Feb	DISC

TESTOLACTONE

TABLET; ORAL
TESLAC

		@	BRISTOL MYERS SQUIBB	50MG	N16118	001		Feb	DISC

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
UNIPHYL

	AB		PURDUE PHARM PRODS	400MG	N87571	001	Sep 01, 1982	Feb	CAHN
	AB	+		600MG	N40086	001	Apr 15, 1996	Feb	CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL
THIORIDAZINE HYDROCHLORIDE

		@	MUTUAL PHARM	50MG	N88370	001	Nov 18, 1983	Feb	DISC

TIROFIBAN HYDROCHLORIDE

INJECTABLE; INJECTION

AGGRASTAT

>D>		+	MEDICURE	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N20912	001	May 14, 1998	Mar	DISC
>A>			@	EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML)	N20912	001	May 14, 1998	Mar	DISC

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

>D>			TOBRAMYCIN							
>D>	AP		ABRAXIS PHARM	EQ 10MG BASE/ML	N65122	001	Nov 29, 2002	Mar	CTNA
>D>	AP	+		EQ 40MG BASE/ML	N65122	002	Nov 29, 2002	Mar	CTNA
>D>	AP		APP PHARMS	EQ 1.2GM BASE/VIAL	N50789	001	Jul 13, 2004	Mar	CTNA
	AP			EQ 1.2GM BASE/VIAL	N50789	001	Jul 13, 2004	Feb	CTEC
>D>	AP	+	X GEN PHARMS	EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Mar	CTNA
	AP	+		EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Feb	CTEC
>D>			TOBRAMYCIN (PHARMACY BULK)							
>D>	AP		ABRAXIS PHARM	EQ 40MG BASE/ML	N65120	001	Nov 29, 2002	Mar	CTNA
>A>			TOBRAMYCIN SULFATE							
>A>	AP		ABRAXIS PHARM	EQ 10MG BASE/ML	N65122	001	Nov 29, 2002	Mar	CTNA
>A>	AP	+		EQ 40MG BASE/ML	N65122	002	Nov 29, 2002	Mar	CTNA
	AP		AKORN STRIDES	EQ 40MG BASE/ML	N65407	001	Mar 11, 2008	Feb	NEWA
>A>	AP		APP PHARMS	EQ 1.2GM BASE/VIAL	N50789	001	Jul 13, 2004	Mar	CTNA
>A>	AP	+	X GEN PHARMS	EQ 1.2GM BASE/VIAL	N65013	001	Aug 17, 2001	Mar	CTNA
>A>			TOBRAMYCIN SULFATE (PHARMACY BULK)							
>A>	AP		ABRAXIS PHARM	EQ 40MG BASE/ML	N65120	001	Nov 29, 2002	Mar	CTNA

TORSEMIDE

TABLET; ORAL

TORSEMIDE

AB		SUN PHARM INDS	5MG	N78478	001	Feb 26, 2008	Feb	NEWA
AB			10MG	N78478	002	Feb 26, 2008	Feb	NEWA
AB			20MG	N78478	003	Feb 26, 2008	Feb	NEWA
AB			100MG	N78478	004	Feb 26, 2008	Feb	NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA		MORTON GROVE	250MG/5ML	N70868	001	Jul 01, 1986	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

		BAYER HLTHCARE	2.5MG	N21400	003	Aug 19, 2003	Jan	CAHN
			5MG	N21400	001	Aug 19, 2003	Jan	CAHN
			10MG	N21400	002	Aug 19, 2003	Jan	CAHN
	+		20MG	N21400	004	Aug 19, 2003	Jan	CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

AP		EBEWE PHARMA	EQ 10MG BASE/ML	N78408	001	Feb 13, 2008	Jan	NEWA

ZIDOVUDINE

TABLET; ORAL
ZIDOVUDINE

AB	MATRIX LABS LTD	300MG		N78922	001	Feb 14, 2008	Jan	NEWA

ZILEUTON

TABLET; ORAL
ZYFLO

	@ CRITICAL	600MG		N20471	003	Dec 09, 1996	Feb	DISC

>A>	AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE							
>A>	CREAM; TOPICAL							
>A>	ANTHELIOS 40							
>A>	+ LOREAL USA	2%;3%;10%;5%	N22009	001	Mar 31, 2008	Mar	NEWA	
	CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE							
	TABLET, CHEWABLE; ORAL							
	CALCIUM CARBONATE, FAMOTIDINE AND MAGNESIUM HYDROXIDE							
	PERRIGO R AND D	800MG;10MG;165MG	N77355	001	Feb 06, 2008	Jan	NEWA	
	CETIRIZINE HYDROCHLORIDE							
	SYRUP; ORAL							
>A>	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY							
>A>	PERRIGO R AND D	5MG/ML	N90254	002	Apr 09, 2008	Mar	NEWA	
>A>	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF							
>A>	PERRIGO R AND D	5MG/ML	N90254	001	Apr 09, 2008	Mar	NEWA	
	CHILDREN'S ZYRTEC ALLERGY							
>D>	+ MCNEIL CONSUMER	1MG/ML	N22155	002	Nov 16, 2007	Mar	CPOT	
>A>	+	5MG/5ML	N22155	002	Nov 16, 2007	Mar	CPOT	
	+	1MG/ML	N22155	002	Nov 16, 2007	Jan	CAHN	
	CHILDREN'S ZYRTEC HIVES RELIEF							
>D>	+ MCNEIL CONSUMER	1MG/ML	N22155	001	Nov 16, 2007	Mar	CPOT	
>A>	+	5MG/5ML	N22155	001	Nov 16, 2007	Mar	CPOT	
	+	1MG/ML	N22155	001	Nov 16, 2007	Jan	CAHN	
	TABLET, CHEWABLE; ORAL							
	CETIRIZINE HYDROCHLORIDE ALLERGY							
	SANDOZ	5MG	N78692	001	Feb 14, 2008	Jan	NEWA	
		10MG	N78692	002	Feb 14, 2008	Jan	NEWA	
	TABLET; ORAL							
	CETIRIZINE HYDROCHLORIDE ALLERGY							
	DR REDDYS LABS LTD	5MG	N78343	004	Jan 15, 2008	Jan	NEWA	
		10MG	N78343	003	Jan 15, 2008	Jan	NEWA	
	CETIRIZINE HYDROCHLORIDE HIVES							
	DR REDDYS LABS LTD	5MG	N78343	001	Jan 15, 2008	Jan	NEWA	
		10MG	N78343	002	Jan 15, 2008	Jan	NEWA	
	ZYRTEC ALLERGY							
	MCNEIL CONSUMER	5MG	N19835	003	Nov 16, 2007	Jan	CAHN	
	+	10MG	N19835	004	Nov 16, 2007	Jan	CAHN	
	ZYRTEC HIVES RELIEF							
	MCNEIL CONSUMER	5MG	N19835	005	Nov 16, 2007	Jan	CAHN	
	+	10MG	N19835	006	Nov 16, 2007	Jan	CAHN	
	CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE							
	TABLET, EXTENDED RELEASE; ORAL							
	CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
	SANDOZ	5MG;120MG	N77991	001	Mar 05, 2008	Feb	NEWA	
	TEVA PHARMS	5MG;120MG	N77170	001	Feb 25, 2008	Feb	NEWA	
	ZYRTEC-D 12 HOUR							
	+ MCNEIL	5MG;120MG	N21150	002	Nov 09, 2007	Jan	CAHN	

MENTHOL; METHYL SALICYLATE

PATCH; TOPICAL

	SALONPAS							
+	HISAMITSU	3%;10%		N22029	001	Feb 20, 2008	Feb	NEWA

MINOXIDIL

SOLUTION; TOPICAL

	MINOXIDIL (FOR WOMEN)							
>A>	HI TECH PHARMA	2%		N74731	002	May 11, 2005	Mar	NEWA

POTASSIUM IODIDE

TABLET; ORAL

	THYROSAFE							
+	RECIP	65MG		N76350	001	Sep 10, 2002	Jan	CAHN

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 03 MARCH 2008

NO MARCH 2008 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MARCH 2008 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ACARBOSE - PRECOSE							
020482 001	**>A>**	4904769	Sep 06, 2009		Y		
ACARBOSE - PRECOSE							
020482 002	**>A>**	4904769	Sep 06, 2009		Y		
ACARBOSE - PRECOSE							
020482 004	**>A>**	4904769	Sep 06, 2009		Y		
ADEFOVIR DIPIVOXIL - HEPSERA							
021449 001						NPP	Dec 19, 2010
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
075710 001						**>A>** PC	Aug 04, 2008
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
075710 002						**>A>** PC	Aug 04, 2008
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
075710 003						PC	Aug 04, 2008
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
075710 004						**>A>** PC	Aug 04, 2008
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
075710 005						**>A>** PC	Aug 04, 2008
ALENDRONATE SODIUM - ALENDRONATE SODIUM							
076184 001						PC	Aug 04, 2008
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
022107 001						NCE	Mar 05, 2012
						NC	Jan 18, 2011
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
022107 002						NCE	Mar 05, 2012
						NC	Jan 18, 2011
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
022107 003						NCE	Mar 05, 2012
						NC	Jan 18, 2011
ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT							
022107 004						NCE	Mar 05, 2012
						NC	Jan 18, 2011
ALOSETRON HYDROCHLORIDE - LOTRONEX							
021107 001						**>A>** D-113	Apr 01, 2011
ALOSETRON HYDROCHLORIDE - LOTRONEX							
021107 002						**>A>** D-113	Apr 01, 2011
APREPITANT - EMEND							
021549 001		5719147	Apr 17, 2015	DS DP	U-853		
		7214692	Sep 18, 2012		U-853		
APREPITANT - EMEND							
021549 002		7214692	Sep 18, 2012		U-853		
APREPITANT - EMEND							
021549 003		7214692	Sep 18, 2012		U-853		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARFORMOTEROL TARTRATE - BROVANA						
021912 001	6040344	Nov 12, 2016	DS			
	6472563	Nov 09, 2021	DS			
	6720453	Nov 09, 2021	DS			
	7145036	Nov 09, 2021	DS			
ARIPIPRAZOLE - ABILIFY						
021436 001					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021436 002					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021436 003					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021436 004					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021436 005					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021436 006					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021713 001					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021729 002					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021729 003					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY						
021729 004					D-110	Oct 29, 2010
					I-555	Feb 27, 2011
					PED	Aug 27, 2011
					PED	Apr 29, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY							
021729 005						D-110	Oct 29, 2010
						I-555	Feb 27, 2011
						PED	Aug 27, 2011
						PED	Apr 29, 2011
ARIPIPRAZOLE - ABILIFY							
021866 001						D-110	Oct 29, 2010
						I-555	Feb 27, 2011
						PED	Aug 27, 2011
						PED	Apr 29, 2011
ATAZANAVIR SULFATE - REYATAZ							
021567 001						**>A>** NPP	Mar 25, 2011
ATAZANAVIR SULFATE - REYATAZ							
021567 002						**>A>** NPP	Mar 25, 2011
ATAZANAVIR SULFATE - REYATAZ							
021567 003						**>A>** NPP	Mar 25, 2011
ATAZANAVIR SULFATE - REYATAZ							
021567 004						**>A>** NPP	Mar 25, 2011
AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE - ANTHELIOS 40							
022009 001						**>A>** NP	Mar 31, 2011
						>A> NC	Oct 05, 2009
BENDAMUSTINE HYDROCHLORIDE - TREANDA							
022249 001						**>A>** NCE	Mar 20, 2013
						>A> ODE	Mar 20, 2015
BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX							
021852 001	**>A>**	RE39706	Jun 09, 2015	DS DP			
BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN							
021398 001		7030149	Apr 19, 2022	U-849			
	>A>	7320976	Apr 19, 2022	U-849			
		7323463	Jan 19, 2023	DP			
BUDESONIDE - RHINOCORT							
020746 001	**>A>**	6291445	Apr 29, 2017		Y		
	>A>	6686346	Apr 29, 2017	DP U-557	Y		
	>A>	6986904	Apr 29, 2017	DP U-699	Y		
BUPROPION HYDROCHLORIDE - WELLBUTRIN XL							
021515 001	**>A>**	6143327	Oct 30, 2018		Y		
CALCIPOTRIENE - DOVONEX							
020554 001	**>A>**	RE39706	Jun 09, 2015	DS DP			
CALCIPOTRIENE - DOVONEX							
020611 001	**>A>**	RE39706	Jun 09, 2015	DS DP			
CARVEDILOL - COREG							
020297 001		RE40000	Jun 07, 2015	U-233			
		RE40000*PED	Dec 07, 2015				
CARVEDILOL - COREG							
020297 002		RE40000	Jun 07, 2015	U-233			
		RE40000*PED	Dec 07, 2015				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARVEDILOL - COREG						
020297 003	RE40000	Jun 07, 2015	U-233			
	RE40000*PED	Dec 07, 2015				
CARVEDILOL - COREG						
020297 004	RE40000	Jun 07, 2015	U-233			
	RE40000*PED	Dec 07, 2015				
CARVEDILOL PHOSPHATE - COREG CR						
022012 001	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
CARVEDILOL PHOSPHATE - COREG CR						
022012 002	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
CARVEDILOL PHOSPHATE - COREG CR						
022012 003	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
CARVEDILOL PHOSPHATE - COREG CR						
022012 004	RE40000	Jun 07, 2015	U-777			
	RE40000*PED	Dec 07, 2015				
CASPOFUNGIN ACETATE - CANCIDAS						
021227 001	**>A>** 5378804	Mar 16, 2013	DS			
	>A> 5378804*PED	Sep 16, 2013				
	>A> 5514650	Jan 26, 2015	DP U-607			
	>A> 5514650*PED	Jul 26, 2015				
	>A> 5792746	Mar 16, 2013	DS DP U-607			
	>A> 5792746*PED	Sep 16, 2013				
	>A> 5952300	Mar 28, 2017	DP			
	>A> 5952300*PED	Sep 28, 2017				
	>A> 6136783	Mar 28, 2017	U-607			
	>A> 6136783*PED	Sep 28, 2017				
CASPOFUNGIN ACETATE - CANCIDAS						
021227 002	**>A>** 5378804	Mar 16, 2013	DS			
	>A> 5378804*PED	Sep 16, 2013				
	>A> 5514650	Jan 26, 2015	DP U-607			
	>A> 5514650*PED	Jul 26, 2015				
	>A> 5792746	Mar 16, 2013	DS DP U-607			
	>A> 5792746*PED	Sep 16, 2013				
	>A> 5952300	Mar 28, 2017	DP			
	>A> 5952300*PED	Sep 28, 2017				
	>A> 6136783	Mar 28, 2017	U-607			
	>A> 6136783*PED	Sep 28, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CICLESONIDE - ALVESCO						
021658 002	5482934	Jan 09, 2013	DS DP U-645			
	5482934	Jan 09, 2013	DS DP U-675			
	5482934	Jan 09, 2013	DS DP U-738			
	5482934	Jan 09, 2013	DS DP U-754			
	5482934	Jan 09, 2013	DS DP U-841			
	5482934	Jan 09, 2013	DS DP U-228			
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP U-675			
	5695743	Jul 06, 2010	DP U-645			
	5695743	Jul 06, 2010	DP U-738			
	5695743	Jul 06, 2010	DP U-754			
	5695743	Jul 06, 2010	DP U-841			
	5695743	Jul 06, 2010	DP U-228			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2013	DP			
CICLESONIDE - ALVESCO						
021658 003	5482934	Jan 09, 2013	DS DP U-645			
	5482934	Jan 09, 2013	DS DP U-675			
	5482934	Jan 09, 2013	DS DP U-738			
	5482934	Jan 09, 2013	DS DP U-754			
	5482934	Jan 09, 2013	DS DP U-841			
	5482934	Jan 09, 2013	DS DP U-228			
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5695743	Jul 06, 2010	DP U-675			
	5695743	Jul 06, 2010	DP U-645			
	5695743	Jul 06, 2010	DP U-738			
	5695743	Jul 06, 2010	DP U-754			
	5695743	Jul 06, 2010	DP U-841			
	5695743	Jul 06, 2010	DP U-228			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2013	DP			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE						
077763 001					**>A>** PC	Sep 16, 2008
CLOFARABINE - CLOLAR						
021673 001	5661136	Jan 14, 2018	U-626			
CLOPIDOGREL BISULFATE - PLAVIX						
020839 001	**>A>** 5576328	Jan 31, 2014	U-432	Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
COLESEVELAM HYDROCHLORIDE - WELCHOL						
021176 001	5919832	Apr 29, 2014	DS		I-553	Jan 18, 2011
	6066678	Apr 29, 2014	DS U-323			
	6433026	Apr 29, 2014	DS			
	6784254	Apr 29, 2014	DS DP			
	7229613	Apr 17, 2022	U-851			
DAPTOMYCIN - CUBICIN						
021572 002	RE39071	Jun 15, 2016	DS DP U-728			
DARIFENACIN HYDROBROMIDE - ENABLEX						
021513 001	5096890	Mar 13, 2015	DS DP U-631			
DARIFENACIN HYDROBROMIDE - ENABLEX						
021513 002	5096890	Mar 13, 2015	DS DP U-631			
DARUNAVIR ETHANOLATE - PREZISTA						
021976 002					NCE	Jun 23, 2011
DESVENLAFAXINE SUCCINATE - PRISTIQ						
021992 001	>A> 6673838	Feb 11, 2022	DS DP U-860		>A> NCE	Mar 01, 2013
	>A> 7291347	Feb 11, 2022	DP			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
021992 002	>A> 6673838	Feb 11, 2022	DS DP U-860		>A> NCE	Mar 01, 2013
	>A> 7291347	Feb 11, 2022	DP			
DEXTROAMPHETAMINE SULFATE - DEXTROAMPHETAMINE SULFATE						
076814 001					PC	Aug 04, 2008
DIVALPROEX SODIUM - DEPAKOTE						
019680 001					>A> M-34	Mar 24, 2011
					>A> PED	Sep 24, 2011
DIVALPROEX SODIUM - DEPAKOTE ER						
021168 001					>A> M-34	Mar 24, 2011
					>A> PED	Sep 24, 2011
DIVALPROEX SODIUM - DEPAKOTE ER						
021168 002					>A> M-34	Mar 24, 2011
					>A> PED	Sep 24, 2011
DONEPEZIL HYDROCHLORIDE - ARICEPT						
020690 001	>A> 6372760	Mar 31, 2019		Y		
DONEPEZIL HYDROCHLORIDE - ARICEPT						
020690 002	>A> 6372760	Mar 31, 2019		Y		
DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT						
020869 001	>A> 6248735	Apr 17, 2011		Y		
	>A> 6316443	Apr 17, 2011	DP U-561	Y		
ELETRIPTAN HYDROBROMIDE - RELPAX						
021016 001	6110940	Aug 29, 2017				
ELETRIPTAN HYDROBROMIDE - RELPAX						
021016 002	6110940	Aug 29, 2017				
ENFUVIRTIDE - FUZEON						
021481 001	>A> 6133418	Nov 17, 2015	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ENTECAVIR - BARACLUDE						
021797 001	5206244	Feb 21, 2015	DS			
ENTECAVIR - BARACLUDE						
021797 002	5206244	Feb 21, 2015	DS			
ENTECAVIR - BARACLUDE						
021798 001	5206244	Feb 21, 2015	DS			
EPLERENONE - INSPRA						
021437 001					M-72	Jan 31, 2011
					PED	Jul 31, 2011
EPLERENONE - INSPRA						
021437 002					M-72	Jan 31, 2011
					PED	Jul 31, 2011
ESCITALOPRAM OXALATE - LEXAPRO						
021323 001	**>A>** 6916941	Aug 12, 2022	DS DP			
	>A> 6916941*PED	Feb 12, 2023	DS DP			
ESCITALOPRAM OXALATE - LEXAPRO						
021323 002	**>A>** 6916941	Aug 12, 2022	DS DP			
	>A> 6916941*PED	Feb 12, 2023	DS DP			
ESCITALOPRAM OXALATE - LEXAPRO						
021323 003	**>A>** 6916941	Aug 12, 2022	DS DP			
	>A> 6916941*PED	Feb 12, 2023	DS DP			
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
022101 001	**>A>** 5690960	Nov 25, 2014	DP U-858		**>A>** I-504	Oct 11, 2009
	>A> 5690960*PED	May 25, 2015			**>A>** NPP	Feb 27, 2011
	>A> 5714504	Feb 03, 2015	DP U-858			
	>A> 5714504*PED	Aug 03, 2015				
	>A> 5877192	May 27, 2014	U-858			
	>A> 5877192*PED	Nov 27, 2014				
	>A> 5900424	May 04, 2016	DS U-858			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-858			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-858			
	>A> 6428810*PED	May 03, 2020				
	>A> 6875872	May 27, 2014	DS			
	>A> 6875872*PED	Nov 27, 2014				
ESTRADIOL; NORGESTIMATE - PREFEST						
021040 001	7320970	Mar 30, 2020	DP U-844			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
021840 001	7320969	Jan 30, 2024	U-828			
ETRAVIRINE - INTELENCE						
022187 001					NCE	Jan 18, 2013
EXENATIDE SYNTHETIC - BYETTA						
021773 001	5424286	Dec 01, 2016	U-653			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE - ZETIA						
021445 001	5846966	Sep 21, 2013	U-474		I-493	May 23, 2009
	5846966*PED	Mar 21, 2014			PED	Nov 23, 2009
	7030106	Jan 25, 2022	DP			
	7030106*PED	Jul 25, 2022				
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
021687 001	5846966	Sep 21, 2013	DP U-593		**>A>** M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			**>A>** M-58	Mar 16, 2009
	>A> 7229982	Dec 11, 2023	DP U-592		**>A>** PED	Apr 03, 2010
	>A> 7229982*PED	Jun 11, 2024			**>A>** PED	Sep 16, 2009
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
021687 002	5846966	Sep 21, 2013	DP U-593		**>A>** M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			**>A>** M-58	Mar 16, 2009
	>A> 7229982	Dec 11, 2023	DP U-592		**>A>** PED	Apr 03, 2010
	>A> 7229982*PED	Jun 11, 2024			**>A>** PED	Sep 16, 2009
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
021687 003	5846966	Sep 21, 2013	DP U-593		**>A>** M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			**>A>** M-58	Mar 16, 2009
	>A> 7229982	Dec 11, 2023	DP U-592		**>A>** PED	Apr 03, 2010
	>A> 7229982*PED	Jun 11, 2024			**>A>** PED	Sep 16, 2009
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
021687 004	5846966	Sep 21, 2013	DP U-593		**>A>** M-60	Oct 03, 2009
	5846966*PED	Mar 21, 2014			**>A>** M-58	Mar 16, 2009
	>A> 7229982	Dec 11, 2023	DP U-592		**>A>** PED	Apr 03, 2010
	>A> 7229982*PED	Jun 11, 2024			**>A>** PED	Sep 16, 2009
	RE37721	Oct 25, 2016	DS DP U-473			
	RE37721*PED	Apr 25, 2017				
FAMOTIDINE - PEPCID AC						
020801 001	**>A>** 5667794	May 02, 2015		Y		
FENOFIBRATE - TRICOR						
021656 001	7320802	Feb 21, 2023	U-847			
FENOFIBRATE - TRICOR						
021656 002	7320802	Feb 21, 2023	U-847			
FENTANYL CITRATE - FENTORA						
021947 006	6200604	Mar 26, 2019	U-767			
	6974590	Mar 26, 2019	U-767			
FLUOCINONIDE - VANOS						
021758 001	**>A>** 7220424	Jan 07, 2023	U-861			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 002	**>A>**	5945416	Mar 24, 2017	DS DP	Y		
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 003	**>A>**	5945416	Mar 24, 2017	DS DP	Y		
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 004	**>A>**	5945416	Mar 24, 2017	DS DP	Y		
FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX							
021520 005	**>A>**	5945416	Mar 24, 2017	DS DP	Y		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50							
021077 001		RE40045	Sep 07, 2010	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50							
021077 002		RE40045	Sep 07, 2010	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50							
021077 003		RE40045	Sep 07, 2010	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
021254 001		RE40045	Sep 07, 2010	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
021254 002		RE40045	Sep 07, 2010	DP			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA							
021254 003		RE40045	Sep 07, 2010	DP			
FLUVOXAMINE MALEATE - LUVOX CR							
022033 001						NDF	Feb 28, 2011
FLUVOXAMINE MALEATE - LUVOX CR							
022033 002						NDF	Feb 28, 2011
FOSAPREPITANT DIMEGLUMINE - EMEND							
022023 001		5512570	Mar 04, 2014	U-850			
		5538982	Jul 23, 2013	U-850			
		5691336	Mar 04, 2014	DS DP			
		5716942	Feb 10, 2015	U-850			
		7214692	Sep 18, 2012	U-850			
GADOBENATE DIMEGLUMINE - MULTIHANCE							
021357 001	**>A>**	4916246	Apr 10, 2012	DS			
GADOBENATE DIMEGLUMINE - MULTIHANCE							
021357 002	**>A>**	4916246	Apr 10, 2012	DS			
GADOBENATE DIMEGLUMINE - MULTIHANCE							
021357 003	**>A>**	4916246	Apr 10, 2012	DS			
GADOBENATE DIMEGLUMINE - MULTIHANCE							
021357 004	**>A>**	4916246	Apr 10, 2012	DS			
GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK							
021358 001	**>A>**	4916246	Apr 10, 2012	DS			
GADOBENATE DIMEGLUMINE - MULTIHANCE MULTIPACK							
021358 002	**>A>**	4916246	Apr 10, 2012	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
021700 004		5002953	Sep 17, 2011	DS DP U-840			
GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL							
021700 005		5002953	Sep 17, 2011	DS DP U-840			
GRANISETRON HYDROCHLORIDE - GRANISETRON HYDROCHLORIDE							
077177 001						PC	Jun 28, 2008
GRANISETRON HYDROCHLORIDE - GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE							
077165 001						PC	Jun 28, 2008
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR							
020387 001	**>A>**	5608075	Mar 04, 2014		Y		
HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM - HYZAAR							
020387 002	**>A>**	5608075	Mar 04, 2014		Y		
INSULIN ASPART RECOMBINANT - NOVOLOG							
020986 001						**>A>** D-112	Mar 14, 2011
LAMIVUDINE - EPIVIR							
020564 001		5047407	Nov 17, 2009	DS DP U-257			
LATANOPROST - XALATAN							
020597 001	**>A>**	5422368	Mar 22, 2011	DP U-778	Y		
LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL							
022157 001		5698558	Sep 24, 2012	U-852		**>A>** NP	May 25, 2010
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN							
020140 001	**>A>**	6500829	Dec 31, 2019	DS DP		**>A>** NP **>A>** ODE	Mar 07, 2011 Mar 07, 2015
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
021977 004		7105486	Jun 29, 2023	U-842			
		7223735	Jun 29, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
021977 005		7105486	Jun 29, 2023	U-842			
		7223735	Jun 29, 2023	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE							
021977 006		7105486	Jun 29, 2023	U-842			
		7223735	Jun 29, 2023	DP			
LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM ADVANCED							
020606 001	**>A>**	5248505	Jul 28, 2010		Y		
	>A>	5612054	Sep 28, 2010		Y		
	>A>	5679376	Oct 21, 2014		Y		
	>A>	5716641	May 21, 2012	U-226	Y		
LOPINAVIR; RITONAVIR - KALETRA							
021226 001	**>A>**	5914332	Dec 13, 2015	U-351			
	>A>	5914332*PED	Jun 13, 2016				
	>A>	6284767	Feb 14, 2016	U-401			
	>A>	6284767*PED	Aug 14, 2016				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOPINAVIR; RITONAVIR - KALETRA						
021251 001	**>A>** 5914332	Dec 13, 2015	U-351			
	>A> 5914332*PED	Jun 13, 2016				
	>A> 6284767	Feb 14, 2016	U-401			
	>A> 6284767*PED	Aug 14, 2016				
LOPINAVIR; RITONAVIR - KALETRA						
021906 001	**>A>** 5914332	Dec 13, 2015	DS DP U-688			
	>A> 5914332*PED	Jun 13, 2016				
	>A> 6284767	Feb 14, 2016	DP U-688			
	>A> 6284767*PED	Aug 14, 2016				
	>A> 7148359	Jul 19, 2019	DP			
	>A> 7148359*PED	Jan 19, 2020				
LOPINAVIR; RITONAVIR - KALETRA						
021906 002	**>A>** 5541206	Jul 30, 2013	DS DP U-688			
	>A> 5541206*PED	Jan 30, 2014				
	>A> 5635523	Jun 03, 2014	U-688			
	>A> 5635523*PED	Dec 03, 2014				
	>A> 5648497	Jul 15, 2014	DS DP			
	>A> 5648497*PED	Jan 15, 2015				
	>A> 5674882	Oct 07, 2014	U-688			
	>A> 5674882*PED	Apr 07, 2015				
	>A> 5846987	Dec 29, 2012	U-688			
	>A> 5846987*PED	Jun 29, 2013				
	>A> 5886036	Nov 19, 2013	DS DP			
	>A> 5886036*PED	May 19, 2014				
	>A> 5914332	Dec 13, 2015	DS DP U-688			
	>A> 5914332*PED	Jun 13, 2016				
	>A> 6037157	Jun 26, 2016	U-688			
	>A> 6037157*PED	Dec 26, 2016				
	>A> 6284767	Feb 14, 2016	DP U-688			
	>A> 6284767*PED	Aug 14, 2016				
	>A> 6703403	Jun 26, 2016	U-688			
	>A> 6703403*PED	Dec 26, 2016				
	>A> 7148359	Jul 19, 2019	DP			
	>A> 7148359*PED	Jan 19, 2020				
LOSARTAN POTASSIUM - COZAAR						
020386 001	**>A>** 5608075	Mar 04, 2014		Y		
LOSARTAN POTASSIUM - COZAAR						
020386 002	**>A>** 5608075	Mar 04, 2014		Y		
LOSARTAN POTASSIUM - COZAAR						
020386 003	**>A>** 5608075	Mar 04, 2014		Y		
MENTHOL; METHYL SALICYLATE - SALONPAS						
022029 001					NDF	Feb 20, 2011
					NC	Feb 20, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
021410 001	**>A>** 5741803	Apr 21, 2015	DS DP U-734	Y		
	>A> 5741803	Apr 21, 2015	DS DP U-493	Y		
	>A> 5965584	Jun 19, 2016	U-493	Y		
	>A> 6166042	Jun 19, 2016	U-493	Y		
	>A> 6288095	Feb 11, 2017	U-493	Y		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
021410 002	**>A>** 5741803	Apr 21, 2015	DS DP U-734	Y		
	>A> 5741803	Apr 21, 2015	DS DP U-493	Y		
	>A> 5965584	Jun 19, 2016	U-493	Y		
	>A> 6166042	Jun 19, 2016	U-493	Y		
	>A> 6288095	Feb 11, 2017	U-493	Y		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
021410 003	**>A>** 5741803	Apr 21, 2015	DS DP U-734	Y		
	>A> 5741803	Apr 21, 2015	DS DP U-493	Y		
	>A> 5965584	Jun 19, 2016	U-493	Y		
	>A> 6166042	Jun 19, 2016	U-493	Y		
	>A> 6288095	Feb 11, 2017	U-493	Y		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
021410 004	**>A>** 5741803	Apr 21, 2015	DS DP U-734	Y		
	>A> 5741803	Apr 21, 2015	DS DP U-493	Y		
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
021410 005	**>A>** 5741803	Apr 21, 2015	DS DP U-734	Y		
	>A> 5741803	Apr 21, 2015	DS DP U-493	Y		
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
022044 001	7326708	Apr 11, 2026	DS DP U-802			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET						
022044 002	7326708	Apr 11, 2026	DS DP U-802			
MICAFUNGIN SODIUM - MYCAMINE						
021506 002	6107458	Sep 29, 2015	DS DP U-845		I-554	Jan 22, 2011
	6107458	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
MICAFUNGIN SODIUM - MYCAMINE						
021506 003	5376634	Dec 27, 2011	DS DP		I-554	Jan 22, 2011
					NCE	Mar 16, 2010
	6107458	Sep 29, 2015	DS DP U-845			
	6107458	Sep 29, 2015	DS DP U-650			
	6265536	Sep 29, 2015	DS DP U-845			
	6265536	Sep 29, 2015	DS DP U-650			
	6774104	Jan 08, 2021	DP U-845			
	6774104	Jan 08, 2021	DP U-650			
MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION						
021026 001	**>A>** 4911932	Mar 27, 2009	DP U-718			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MODAFINIL - PROVIGIL						
020717 001	7297346	Nov 29, 2023	DP			
MODAFINIL - PROVIGIL						
020717 002	7297346	Nov 29, 2023	DP			
MOMETASONE FUROATE - ASMANEX TWISTHALER						
021067 001					NPP	Feb 01, 2011
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
021742 002	5759580	Jun 02, 2015	DP			
	6545040	Apr 08, 2020	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
021742 003	5759580	Jun 02, 2015	DP			
	6545040	Apr 08, 2020	DP U-3			
NEBIVOLOL HYDROCHLORIDE - BYSTOLIC						
021742 004	5759580	Jun 02, 2015	DP			
	6545040	Apr 08, 2020	DP U-3			
NESIRITIDE RECOMBINANT - NATRECOR						
020920 001	5114923	May 19, 2014	DS DP U-855			
NIACIN; SIMVASTATIN - SIMCOR						
022078 001	**>A>** 6080428	May 27, 2017	U-862		NC	Feb 15, 2011
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6406715	Sep 20, 2013	DP			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6746691	Sep 20, 2013	DP			
	>A> 6818229	Feb 15, 2014	DP			
	>A> 7011848	Sep 20, 2013	U-862			
NIACIN; SIMVASTATIN - SIMCOR						
022078 002	**>A>** 6080428	May 27, 2017	U-862		NC	Feb 15, 2011
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6406715	Sep 20, 2013	DP			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6746691	Sep 20, 2013	DP			
	>A> 6818229	Feb 15, 2014	DP			
	>A> 7011848	Sep 20, 2013	U-862			
NIACIN; SIMVASTATIN - SIMCOR						
022078 003	**>A>** 6080428	May 27, 2017	U-862		NC	Feb 15, 2011
	>A> 6129930	Sep 20, 2013	DP U-862			
	>A> 6406715	Sep 20, 2013	DP			
	>A> 6469035	Mar 15, 2018	U-863			
	>A> 6676967	Sep 20, 2013	U-862			
	>A> 6746691	Sep 20, 2013	DP			
	>A> 6818229	Feb 15, 2014	DP			
	>A> 7011848	Sep 20, 2013	U-862			
NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA						
022068 001					**>A>** ODE	Oct 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NISOLDIPINE - SULAR						
020356 005	5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
NISOLDIPINE - SULAR						
020356 006	5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
NISOLDIPINE - SULAR						
020356 007	5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
NISOLDIPINE - SULAR						
020356 008	5422123	Jun 06, 2012	DP			
	5626874	Nov 30, 2014	DP			
OLMESARTAN MEDOXOMIL - BENICAR						
021286 001	**>A>** 6878703	Nov 19, 2021	U-3	Y		
OLMESARTAN MEDOXOMIL - BENICAR						
021286 003	**>A>** 6878703	Nov 19, 2021	U-3	Y		
OLMESARTAN MEDOXOMIL - BENICAR						
021286 004	**>A>** 6878703	Nov 19, 2021	U-3	Y		
OMEPRAZOLE MAGNESIUM - PRILOSEC						
022056 001					**>A>** NPP	Mar 20, 2011
					>A> PED	Sep 20, 2011
OMEPRAZOLE MAGNESIUM - PRILOSEC						
022056 002					**>A>** NPP	Mar 20, 2011
					>A> PED	Sep 20, 2011
OXCARBAZEPINE - OXCARBAZEPINE						
078069 001					PC	Apr 06, 2008
OXCARBAZEPINE - OXCARBAZEPINE						
078069 002					PC	Apr 06, 2008
OXCARBAZEPINE - OXCARBAZEPINE						
078069 003					PC	Apr 06, 2008
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
021610 005					**>A>** NDF	Jun 22, 2009
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
021610 006					**>A>** NDF	Jun 22, 2009
OXYMORPHONE HYDROCHLORIDE - OPANA ER						
021610 007					**>A>** NDF	Jun 22, 2009
PALONOSETRON HYDROCHLORIDE - ALOXI						
021372 002					**>A>** I-556	Mar 01, 2011
					>A> NS	Mar 01, 2011
					>A> NCE	Jul 25, 2008
PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM						
077056 001					PC	Jun 18, 2008
PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM						
077056 002					PC	Jun 18, 2008
PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM						
077058 001					PC	Jun 18, 2008

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM						
077058 002					PC	Jun 18, 2008
PANTOPRAZOLE SODIUM - PROTONIX						
022020 001	**>A>** 4758579	Jul 19, 2010	DS DP U-859			
PEMETREXED DISODIUM - ALIMTA						
021462 002	5217974	Mar 29, 2011	U-551			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 001	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 002	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 003	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 004	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 005	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 006	**>A>** 4886812	Oct 08, 2010	DS DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX						
020667 007	**>A>** 4886812	Oct 08, 2010	DS DP		I-517	Nov 07, 2009
	6001861	Jan 16, 2018	U-784			
	6194445	Jan 16, 2018	U-784			
PREDNISOLONE ACETATE - FLO-PRED						
022067 001	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
PREDNISOLONE ACETATE - FLO-PRED						
022067 002	5881926	Mar 16, 2016	DP			
	6071523	Jun 03, 2018	DP			
	6102254	Mar 11, 2013	DP			
	6399079	Jun 03, 2018	DP			
	6656482	Jun 03, 2018	DP			
PROGESTERONE - ENDOMETRIN						
022057 001	**>A>** 7300664	Nov 17, 2019	U-856			
	>A> 7320800	Nov 17, 2019	U-856			
RALOXIFENE HYDROCHLORIDE - EVISTA						
020815 001	**>A>** 5393763	Jul 28, 2012	U-114	Y	**>A>** ODE	Sep 13, 2014
	>A> 5457117	Jul 28, 2012	U-114	Y		
	>A> 5478847	Mar 02, 2014	U-114	Y		
RISPERIDONE - RISPERDAL						
020588 001	**>A>** 5616587	Jul 11, 2014		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ROCURONIUM BROMIDE - ZEMURON						
020214 001	**>A>** 4894369	Apr 13, 2008				
	>A> 4894369*PED	Oct 13, 2008				
ROCURONIUM BROMIDE - ZEMURON						
020214 002	**>A>** 4894369	Apr 13, 2008				
	>A> 4894369*PED	Oct 13, 2008				
ROCURONIUM BROMIDE - ZEMURON						
020214 003	**>A>** 4894369	Apr 13, 2008				
	>A> 4894369*PED	Oct 13, 2008				
ROSIGLITAZONE MALEATE - AVANDIA						
021071 002	**>A>** 5741803	Apr 21, 2015	DS DP		U-628	Y
	>A> 5741803	Apr 21, 2015	DS DP		U-329	Y
	>A> 6288095	Feb 11, 2017			U-420	Y
ROSIGLITAZONE MALEATE - AVANDIA						
021071 003	**>A>** 5741803	Apr 21, 2015	DS DP		U-628	Y
	>A> 5741803	Apr 21, 2015	DS DP		U-329	Y
	>A> 6288095	Feb 11, 2017			U-420	Y
ROSIGLITAZONE MALEATE - AVANDIA						
021071 004	**>A>** 5741803	Apr 21, 2015	DS DP		U-628	Y
	>A> 5741803	Apr 21, 2015	DS DP		U-329	Y
	>A> 6288095	Feb 11, 2017			U-420	Y
SEVELAMER CARBONATE - RENVELA						
022127 001	5496545	Aug 11, 2013	DP		U-246	
	5667775	Sep 16, 2014			U-246	
	6509013	Aug 11, 2013	DP			
	6858203	Aug 11, 2013	DP		U-246	
	7014846	Aug 11, 2013	DP		U-246	
SIROLIMUS - RAPAMUNE						
021110 001	**>A>** 5145684	Jan 25, 2011	DP		U-857	
	>A> 5145684*PED	Jul 25, 2011				
SIROLIMUS - RAPAMUNE						
021110 002	**>A>** 5145684	Jan 25, 2011	DP		U-857	
	>A> 5145684*PED	Jul 25, 2011				
SIROLIMUS - RAPAMUNE						
021110 003	**>A>** 5145684	Jan 25, 2011	DP		U-857	
	>A> 5145684*PED	Jul 25, 2011				
SITAGLIPTIN PHOSPHATE - JANUVIA						
021995 001	7326708	Apr 11, 2026	DS DP		U-802	
SITAGLIPTIN PHOSPHATE - JANUVIA						
021995 002	7326708	Apr 11, 2026	DS DP		U-802	
SITAGLIPTIN PHOSPHATE - JANUVIA						
021995 003	7326708	Apr 11, 2026	DS DP		U-802	

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SODIUM OXYBATE - XYREM						
021196 001	6780889	Jul 04, 2020	DP			
	7262219	Jul 04, 2020	DP			
SOMATROPIN RECOMBINANT - ACCRETROPIN						
021538 001					NP	Jan 23, 2011
SOMATROPIN RECOMBINANT - OMNITROPE						
021426 003					NP	May 30, 2009
SORAFENIB TOSYLATE - NEXAVAR						
021923 001					**>A>** ODE	Nov 16, 2014
SUMATRIPTAN SUCCINATE - IMITREX						
020132 001	**>A>** 5863559	Jan 26, 2016	U-72	Y		
	>A> 6020001	Mar 02, 2012	U-444	Y		
	>A> 6368627	Mar 02, 2012	U-444	Y		
SUMATRIPTAN SUCCINATE - IMITREX						
020132 002	**>A>** 5863559	Jan 26, 2016	U-72	Y		
	>A> 6020001	Mar 02, 2012	U-444	Y		
	>A> 6368627	Mar 02, 2012	U-444	Y		
SUMATRIPTAN SUCCINATE - IMITREX						
020132 003	**>A>** 5863559	Jan 26, 2016	U-72	Y		
	>A> 6020001	Mar 02, 2012	U-444	Y		
	>A> 6368627	Mar 02, 2012	U-444	Y		
SUMATRIPTAN SUCCINATE - IMITREX STATDOSE						
020080 002	5037845	Aug 06, 2008	DS DP U-848			
	5037845*PED	Feb 06, 2009				
TADALAFIL - CIALIS						
021368 001					D-111	Jan 07, 2011
TADALAFIL - CIALIS						
021368 004	5859006	Nov 21, 2017	DS DP		D-111	Jan 07, 2011
	6140329	Jul 11, 2016	DP U-155		NCE	Nov 21, 2008
	6821975	Nov 19, 2020	DS DP U-614			
	6821975	Nov 19, 2020	DS DP U-533			
	6943166	Apr 26, 2020	U-155			
	7182958	Apr 26, 2020	DP U-155			
TECHNETIUM TC-99M SESTAMIBI KIT - CARDIOLITE						
019785 001	4988827	Jan 29, 2008				
	4988827*PED	Jul 29, 2008				
TERBINAFINE - LAMISIL AT						
021958 001	6121314	May 18, 2012	U-540			
	6121314	May 18, 2012	U-504			
TESTOSTERONE - TESTIM						
021454 001	7320968	Jan 18, 2025	U-843			
TIGECYCLINE - TYGACIL						
021821 001	5494903	Apr 09, 2016	DS DP			
	>A> RE40086	Jun 25, 2013	U-282			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 3 - March 2008

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA						
021395 001	5478578	Dec 26, 2012	DP			
	7309707	Mar 10, 2023	DS DP			
TIPRANAVIR - APTIVUS						
021814 001	**>A>** 5852195	Jun 22, 2019	DS		**>A>** NCE	Jun 22, 2010
	>A> 5852195*PED	Dec 22, 2019			**>A>** PED	Dec 22, 2010
	>A> 6147095	Oct 29, 2019	U-670			
	>A> 6147095*PED	Apr 29, 2020				
	>A> 6169181	May 06, 2014	DS			
	>A> 6169181*PED	Nov 06, 2014				
	>A> 6231887	Jul 27, 2018	DP			
	>A> 6231887*PED	Jan 27, 2019				
TRIAMCINOLONE ACETONIDE - TRIESENCE						
022048 001	6395294	Jan 13, 2020	DP U-846			
VALACYCLOVIR HYDROCHLORIDE - VALTREX						
020487 001	4957924	Jun 23, 2009	U-530			
	4957924*PED	Dec 23, 2009				
	5879706	Jan 19, 2016	U-530			
	5879706*PED	Jul 19, 2016				
	6107302	Jan 19, 2016	U-530			
	6107302*PED	Jul 19, 2016				
VALACYCLOVIR HYDROCHLORIDE - VALTREX						
020487 002	4957924	Jun 23, 2009	U-530			
	4957924*PED	Dec 23, 2009				
	5879706	Jan 19, 2016	U-530			
	5879706*PED	Jul 19, 2016				
	6107302	Jan 19, 2016	U-530			
	6107302*PED	Jul 19, 2016				
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
021304 001	6083953	Mar 29, 2015	DS DP U-854			
	6083953	Mar 29, 2015	DS DP U-384			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. Patent number 4904769 listed on all products of NDA 20482 Precose (Acarbose) was requested to be delisted by the sponsor on 4/16/2007. This patent has remained listed because, under Section 505(j)(5)(D)(i) of the Act, a first applicant may retain eligibility for 180-day exclusivity based on a paragraph IV certification to this patent for a certain period.

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

APPL/PROD NO	PATENT NO	PATENT EXPIRATON DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9% - VOLUVEN					
070012 001				NP	Dec 10, 2010

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 28th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm